Author: "Amat-Santos I" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Amat-Santos I"' showing total 121 results

Start Over Author "Amat-Santos I"

121 results on '"Amat-Santos I"'

1. Sex differences in treatment strategy for coronary artery aneurysms: Insights from the international Coronary Artery Aneurysm Registry

Author: Arslan, F., Núñez-Gil, I. J., Rodríguez-Olivares, R., Cerrato, E., Bollati, M., Nombela-Franco, L., Terol, B., Alfonso-Rodríguez, E., Camacho Freire, S. J., Villablanca, P. A., Amat Santos, I. J., De la Torre Hernández, J. M., Pascual, I., Liebetrau, C., Alkhouli, M., and Fernández-Ortiz, A.
Published: 2022
Full Text: View/download PDF

2. Comparison of paravalvular leak and 1-year survival after transcatheter aortic valve replacement with SAPIEN 3 versus EVOLUT PRO valves

Author: Matta, A., primary, Regueiro, A., additional, Urena-Alcazar, M., additional, Nombelo-Franco, L., additional, Riche, M., additional, Rodriguez-Gabella, T., additional, Amat Santos, I., additional, Chamandi, C., additional, Akiki, T., additional, Gabani, R., additional, Vera-Urquiza, R., additional, Lhermusier, T., additional, Bouisset, F., additional, Carrié, D., additional, and Campelo-Parada, F., additional
Published: 2024
Full Text: View/download PDF

3. Syncope at rest in severe aortic stenosis may persist after intervention and is associated with poor outcomes

Author: Garcia, M, primary, Ybarra Falcon, C, additional, Martin Paniagua, S, additional, Lozano Ibanez, A, additional, Alanon Hernandez, A, additional, Cabezon, G, additional, Ramos, N, additional, Amat Santos, I J, additional, Sevilla, T, additional, Revilla, A, additional, Carrasco, M, additional, Lopez, J, additional, Rollan, M J, additional, Vilacosta, I, additional, and San Roman, J A, additional
Published: 2023
Full Text: View/download PDF

4. Safety and feasibility of transradial access for percutaneous coronary intervention in chronic total occlusions

Author: Diego-Nieto A, Nunez J, Minana G, Amat-Santos I, Salinas-Sanguino P, Mohande M, Regueiro A, Pan M, Lacunza J, Caballero-Borrego J, Antonio Fernandez-Diaz J, Cisnal A, Santos-Martinez S, Gonzalo N, Vaquerizo B, Rivero F, Jurado-Roman A, Abellan-Huerta J, Gonzalez E, Rondan-Murillo J, Benito M, Burgo J, Mazuecos J, Ojeda F, Moreno-Ambroj C, Sabate M, Ojeda S, Aguilar R, Perez M, Sanchis J, Campo-Prieto A, Escaned J, Goicolea J, and Martin-Moreiras J
Subjects: General Medicine
Abstract: INTRODUCTION AND OBJECTIVES: Transfemoral access is the most frequently used vascular approach in chronic total occlusion percutaneous coronary interventions (CTO-PCI). The aim of this study was to evaluate the safety and feasibility of a transradial access CTO-PCI program and its impact on angiographic and clinical results and length of hospital stay.; METHODS: Retrospective multicenter cohort study including 2550 consecutive CTO-PCI procedures included in a multicenter registry with accurate information on vascular access. A total of 896 procedures were performed as radial-only access while 1654 were performed through at least 1 femoral puncture. Clinical and angiographic data were collected.; RESULTS: The mean age was 66.3 ± 11.4 years. The mean Japan-chronic total occlusion score (2.7 ± 0.3) was similar in the 2 groups. Successful revascularization was achieved in 2009 (79.6%) cases, 78.2% and 82.1% in the femoral and radial access cohorts, respectively (P = .002). Periprocedural in-hospital complications were observed in 5.1% and 2.3% (P = .02), with fewer access site-dependant vascular complications in the transradial cohort (2.3% vs 0.2%; P = .009). The mean length of hospital stay was significantly shorter in the transradial access group (0.89 ± 1.4 vs 2.2 ± 3.2 days, P < .001).; CONCLUSION: A transradial program for CTO-PCI is safe and effective in most CTO lesions. The transradial strategy has fewer vascular complications and shorter length of hospital stay without compromising the success rate. Copyright © 2022. Published by Elsevier Espana, S.L.U.
Published: 2023
Full Text: View/download PDF

5. Procedural Success in Transaxillary Transcatheter Aortic Valve Implantation According to Type of Transcatheter Heart Valve: Results from the Multicenter TAXI Registry

Author: Schäfer, A., additional, Bhadra, O. D., additional, Conradi, L., additional, Westermann, D., additional, Reichenspurner, H., additional, De Backer, O., additional, Sondergaard, L., additional, Qureshi, W. T., additional, Kakouros, N., additional, Amat-Santos, I., additional, Kaneko, T., additional, Teles, R., additional, Nolasco, T., additional, Abecasis, M., additional, Werner, N., additional, Sacha, J., additional, Trani, C., additional, Mangieri, A., additional, Regueiro, A., additional, Biancari, F., additional, Niemelä, M., additional, Giannini, F., additional, Buono, A., additional, Bruno, F., additional, Savontaus, M., additional, Ielasi, A., additional, Ferraro, P., additional, Biondi-Zoccai, G., additional, Morello, A., additional, and Giordano, A., additional
Published: 2023
Full Text: View/download PDF

6. 14 Morbidly obese patients with symptomatic severe aortic stenosis, what is the optimal treatment strategy? A propensity score matched analysis of transcatheter versus surgical aortic valve replacement

Author: McInerney, A, primary, Rodés-Cabau, J, additional, Veiga, G, additional, Lopez-Otero, D, additional, Muñoz-Garcia, E, additional, Campelo, F, additional, Oteo, JF, additional, Carnero, M, additional, Tafur Soto, JD, additional, Amat-Santos, I, additional, Travieso, A, additional, Mohammadi, S, additional, Barbanti, M, additional, Cheema, AN, additional, Toggweiler, S, additional, Saia, F, additional, Dabrowski, M, additional, Serra, V, additional, Alfonso, F, additional, Barbosa, H, additional, Regueiro, A, additional, Alperi, A, additional, Ongay, AG, additional, Martinez Cereijo, JM, additional, Muñoz-Garcia, AJ, additional, Matta, A, additional, Arellano-Serrano, C, additional, Barrero, A, additional, Tirado-Conte, G, additional, Gonzalo, N, additional, Sanmartin, XC, additional, de la Torre Hernández, JM, additional, Kalavrouziotis, D, additional, Maroto, L, additional, Forteza-Gil, A, additional, Cobiella, J, additional, Escaned, J, additional, and Nombela-Franco, L, additional
Published: 2022
Full Text: View/download PDF

7. Reduction of major adverse and major cardiovascular events in patients with atrial fibrillation and stent implantation treated with left atrial occlusion device vs oral anticoagulants strategy

Author: Lopez-Minguez, J R, primary, Suarez-Corchuelo, E, additional, Lopez-Tejero, S, additional, Nombela-Franco, L, additional, Freixa-Rofastes, X, additional, Bastos-Fernandez, G, additional, Millan-Alvarez, X, additional, Moreno-Gomez, R, additional, Fernandez-Diaz, J A, additional, Amat-Santos, I, additional, Benito-Gonzalez, T, additional, Alfonso-Manterola, F, additional, Navarro-Romero, R, additional, Cruz-Gonzalez, I, additional, and Nogales-Asensio, J M, additional
Published: 2022
Full Text: View/download PDF

8. Long-term effects of coronavirus disease 2019 on the cardiovascular system: the CV COVID-19 registry

Author: Arevalos Rivas, V, primary, Ortega-Paz, L, additional, Fernandez-Rodriguez, D, additional, Jimenez-Diaz, V A, additional, Baneras Rius, J, additional, Campo, G, additional, Diaz, J F, additional, Scardino, C, additional, Rodriguez-Santamarta, M, additional, Gonzalo, N, additional, Perginotti, A, additional, Alfonso, F, additional, Amat-Santos, I, additional, Sabate, M, additional, and Brugaletta, S, additional
Published: 2022
Full Text: View/download PDF

9. Myval versus alternative balloon- and self-expandable transcatheter heart valves: A central core lab analysis of conduction disturbances

Author: Santos-Martinez, S., Halim, J., Castro-Mejia, A., De Marco, F., Trani, Carlo, Martin, P., Infusino, Fabio, Ancona, M., Moreno, R., den Heijer, P., Nombela-Franco, L., Bedogni, Francesco, Sardella, G., Montorfano, M., Revilla-Orodea, A., Delgado-Arana, J. R., Barrero, A., Gomez-Salvador, I., Ijsselmuiden, A. J. J., Redondo, A., Gutierrez, H., Serrador, A., Serruys, P. W., Roman, J. A. S., Amat-Santos, I. J., Trani C. (ORCID:0000-0001-9777-013X), Infusino F., Bedogni F., Santos-Martinez, S., Halim, J., Castro-Mejia, A., De Marco, F., Trani, Carlo, Martin, P., Infusino, Fabio, Ancona, M., Moreno, R., den Heijer, P., Nombela-Franco, L., Bedogni, Francesco, Sardella, G., Montorfano, M., Revilla-Orodea, A., Delgado-Arana, J. R., Barrero, A., Gomez-Salvador, I., Ijsselmuiden, A. J. J., Redondo, A., Gutierrez, H., Serrador, A., Serruys, P. W., Roman, J. A. S., Amat-Santos, I. J., Trani C. (ORCID:0000-0001-9777-013X), Infusino F., and Bedogni F.
Abstract: Background: Several studies have compared surface electrocardiographic changes following different self-expandable (SE) (Evolut (Medtronic, USA); Acurate (Boston Scientific, USA); Portico (Abbott, USA); and Allegra (NVT, Germany)) and balloon-expandable (BE) Sapien-3 (Edwards Lifesciences, USA) transcatheter heart valves. We aimed to compare these prosthesis with the novel Myval BE prosthesis (Meril Life, India). Methods: Academic European registry of consecutive patients with severe aortic stenosis who received any of the 6 aforementioned valves. Baseline, post-procedural, and discharge 12‐leads electrocardiograms (ECG) were centrally analyzed and compared. Results: A total of 1131 patients were included: 135 Myval (11.9%), 290 Sapien-3 (25.6%), 298 Evolut (26.3%), 180 Acurate (15.9%), 125 Portico (11.1%), and 103 Allegra (9.1%). There were no baseline differences in intraventricular conduction disturbances rate. Compared to the novel BE Myval, there were similar procedural and in-hospital outcomes. Similar rates of early new permanent pacemaker implant (PPI) were observed amongst Myval (7.4%), Sapien-3 (13.4%), and Acurate (9.1%), but Evolut, Portico, and Allegra presented significantly higher rates (18.5%, p = 0.003; 29.5% p < 0.001 and 22%, p = 0.001, respectively). Central analysis of ECGs, unraveled significant prolongation of the PR segment with Evolut, Portico and Allegra whereas Evolut, Acurate, and Portico showed significant QRS widening compared to Myval. However, at discharge no differences in PR segment duration were observed while, Evolut, and Portico– but not Acurate, Allegra or Sapien-3 – still presented significant widening of QRS segment compared to Myval. Conclusions: After blinded central ECG analysis, the novel Myval balloon-expandable prosthesis was associated with a low rate of early conduction disturbances.
Published: 2022

10. Procedural and clinical outcomes after repeat edge-to-edge transcatheter mitral valve repair

Author: Freixa, X, Estevez-Loureiro, R, Pascual, I, Carrasco-Chinchilla, F, Sanchis, L, Nombela-Franco, L, Benito, T, Li, P, Flores-Umanzor, E, Amat-Santos, I, Baz, JA, Jimenez-Quevedo, P, Hernandez, F, Fernandez-Peregrina, E, Alonso-Briales, JH, Avanzas, P, Fernandez-Vazquez, F, and Arzamendi, D
Subjects: mitral valve disease (MVD), structural heart disease intervention (SHDI), percutaneous intervention, mitral valve disease (MVPI)
Abstract: Background and Objectives Evidence regarding redo percutaneous interventions for recurrent mitral regurgitation is scarce. We ought to evaluate procedural and clinical outcomes of repeated edge-to-edge transcatheter mitral valve repair (TMVR) interventions. Methods This multicenter study collected individual data from eight high-volume TMVR Centers in Spain. Between 2012 and 2020, all patients undergoing a second edge-to-edge TMVR intervention (Redo) were included in the study. Results Among a total of 1028 procedures, 31 patients (3%) with residual MR >= 3 at follow-up underwent a second procedure (Redo). Redo intervention was mainly conducted between the first and second year after the first procedure. The most common cause of MR progression was partial detachment (46.7%) followed by LV remodeling (35.5%). Procedural success was achieved in 87% of cases. After a mean follow-up of 1.75 +/- 1.54 years, all-cause and cardiovascular mortality were 48.1% and 25%, respectively. Nearly half of the patients (48.1%) required at least one hospital admission for CHF within the follow-up period. However, most of the patients presented symptomatic improvement as depicted by an NYHA class
Published: 2022

11. Bioactive or Drug Eluting Stents in 75 years or older patients: The BIODES-75 Registry

Author: Cordoba-Soriano J, Gutierrez-Diez A, Del Blanco B, Nunez J, Amat-Santos I, Oteo J, Romaguera R, Gallardo-Lopez A, Lozano Ruiz-Poveda F, Baello P, Aguar P, Jerez-Valero M, Jimenez-Diaz V, Serra B, Cascon J, Morales-Ponce F, Portero-Portaz J, Melehi El Assali D, Cerrato-Garcia P, and Jimenez-Mazuecos J
Abstract: BACKGROUND: TiNO-coated BAS have demonstrated competitive outcomes compared to drug-eluting stents (DES). These devices allow short antiplatelet regimens and may be a good option for the growing elderly population undergoing percutaneous coronary intervention (PCI).; METHODS: Multicenter observational trial in routine clinical practice. A propensity-score matched analysis compared a prospective cohort of patients = 75 years undergoing PCI with BAS, with a contemporary and retrospective cohort treated with last-generation DES. The co-primary endpoints of the study were the Target-Lesion-Failure (Cardiac death, non-fatal myocardial infarction, or target lesion revascularization) and Major Adverse Cardiovascular Events (total death, non-fatal myocardial infarction, stroke, or new revascularization) at 1 year.; RESULTS: Whole population included 1000 patients, and 326 patients in each group were matched for analysis. No differences in primary endpoints were found: TLF 10.4% vs. 11% (HR 0.96 (Confidence Interval 95%, 0.36-1.7; p = 0.87)) and MACE 16.3% vs. 17.2% (HR 0.98 (Confidence Interval 95%; 0.3-1.5, p = 0.93)). Patients treated with BAS received shorter antiplatelets regimens (dual antiplatelet therapy at 1 year, 25.7% vs. 70.6%, p = 0.0001), and they presented lower incidence of bleeding (3.7% vs. 11.7%, HR 0.3 (IC 95% 0.16-0.6, p = 0.001)).; CONCLUSION: In this real-life registry of patients = 75 years, BAS were similar to the latest-generation DES in terms of efficacy and reduced the duration of the antithrombotic therapy, lowering bleeding events. Copyright © 2022 Elsevier Inc. All rights reserved.
Published: 2022

12. Rationale and Design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

Author: Amat-Santos I, Sanchez-Luna J, Abu-Assi E, Melendo Viu M, Cruz-Gonzalez I, Nombela-Franco L, Munoz Garcia A, Garcia Blas S, de la Torre Hernandez J, Romaguera R, Sanchez-Recalde A, Diez Gil J, Lopez Otero D, Gheorge L, Ibanez B, Iniguez Romo A, Raposeiras-Roubin S, Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI), and Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) Investiga
Abstract: AIMS: Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus (DM), reduced left ventricular ejection fraction (LVEF) and chronic kidney disease (CKD). However, the effect of SGLT-2 inhibitors on outcomes after TAVI is unknown. The Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) trial is designed to assess the clinical benefit and safety of the SGLT-2 inhibitor dapagliflozin in patients undergoing TAVI. METHODS: DapaTAVI is an independent pragmatic, controlled, prospective, randomized, open-label blinded end-point, multi-center trial conducted in Spain, evaluating the effect of dapagliflozin 10mg/day on the risk of death and worsening HF in patients with severe AS undergoing a TAVI. Candidate patients should have prior history of HF admission plus =1 of the following criteria: 1) DM, 2) LVEF =40%, or 3) estimated glomerular filtrate rate between 25 and 75mL/min/1.73m2. A total of 1020 patients will be randomized (1:1) to dapagliflozin versus no dapagliflozin. Key secondary outcomes include: (i) Incidence rate of individual components of the primary outcome; (ii) Cardiovascular mortality; (iii) The composite of HF hospitalization or CV death; (iv) Total number of recurrent HF hospitalizations. CONCLUSION: DapaTAVI will determine the efficacy and safety of dapagliflozin in a broad spectrum of frail patients after AS relief by TAVI. This article is protected by copyright. All rights reserved.
Published: 2022

13. The Use of the Acute Pd/Pa Drop After Intracoronary Nitroglycerin Infusion to Rule Out Significant FFR: CANICA (Can Intracoronary Nitroglycerin Predict Fractional Flow Reserve Without Adenosine?) Multicenter Study

Author: Martin-Reyes, R., de la Torre Hernandez, J. M., Franco-Pelaez, J., Lopez-Palop, R., Telleria Arrieta, M., Amat Santos, I. J., Carrillo Saez, P., Sanchez-Recalde, A., Sanmartin Pena, J. C., Garcia Camarero, T., Brugaletta, S., Gimeno de Carlos, F., Pinero, A., Sorto Sanchez, D. C., Frutos, A., Lasa Larraya, G., Navarro, F., and Farre, J.
Published: 2016
Full Text: View/download PDF

14. Post-COVID-19 syndrome: prospective evaluation of clinical and functional outcomes

Author: Ybarra Falcon, C, primary, Aparisi, A, additional, Garcia Gomez, M, additional, Iglesias Echeverria, C, additional, Tobar, J, additional, Ladron, R, additional, Uribarri, A, additional, Jaurrieta Largo, S, additional, Catala, P, additional, Hinojosa, W, additional, Veras Burgos, C, additional, Marcos Mangas, M, additional, Carrasco Moraleja, M, additional, Amat Santos, I J, additional, and San Roman Calvar, A, additional
Published: 2021
Full Text: View/download PDF

15. Clinical and Echocardiographic Outcomes of Transcatheter Mitral Valve Repair in Atrial Functional Mitral Regurgitation

Author: Benito-Gonzalez T, Carrasco F, Estevez Loureiro R, Pascual I, Arzamendi D, Garrote C, Nombela-Franco L, Pan M, Serrador A, Freixa X, Andraka L, Cruz-Gonzalez I, Ramon Lopez-Minguez J, Diez-Gil J, Urbano Carrillo C, Sanmiguel D, Sanchis Fores J, Ruiz Quevedo V, Molina Navarro E, Becerra-Munoz V, Avanzas P, Li C, Jimenez-Quevedo P, Mesa Rubio D, Amat-Santos I, Regueiro A, Trillo Nouche R, Alonso Brailes J, and Fernandez-Vazquez F
Published: 2021

16. Next-generation balloon-expandable Myval transcatheter heart valve in low-risk aortic stenosis patients

Author: Garcia-Gomez, M., Delgado-Arana, J. R., Halim, J., De Marco, F., Trani, C., Martin, P., Won-Keun, K., Montorfano, M., den Heijer, P., Bedogni, F., Sardella, G., IJsselmuiden, A. J. J., Campante Teles, R., Aristizabal-Duque, C. H., Gordillo, X., Santos-Martinez, S., Barrero, A., Gomez-Salvador, I., Ancona, M., Redondo, A., Roman, J. A. S., Amat-Santos, I. J., Trani C. (ORCID:0000-0001-9777-013X), Bedogni F., Garcia-Gomez, M., Delgado-Arana, J. R., Halim, J., De Marco, F., Trani, C., Martin, P., Won-Keun, K., Montorfano, M., den Heijer, P., Bedogni, F., Sardella, G., IJsselmuiden, A. J. J., Campante Teles, R., Aristizabal-Duque, C. H., Gordillo, X., Santos-Martinez, S., Barrero, A., Gomez-Salvador, I., Ancona, M., Redondo, A., Roman, J. A. S., Amat-Santos, I. J., Trani C. (ORCID:0000-0001-9777-013X), and Bedogni F.
Abstract: Objectives: We aimed to describe hemodynamic performance and clinical outcomes at 30-day follow-up of the balloon-expandable (BE) Myval transcatheter heart valve (THV) in low-risk patients. Background: The results of the next-generation BE Myval THV in low-risk aortic stenosis (AS) patients are still unknown. Methods: Retrospective registry performed in nine European centers including patients with low predicted operative mortality risk according to Society of thoracic surgeons (STS) and European system for cardiac operative risk evaluation (EuroSCORE-II) scores. Results: Between September 2019 and February 2021, a total of 100 patients (51% males, mean age 80 ± 6.5 years) were included. Mean STS score and EuroSCORE-II were 2.4 ± 0.8% and 2.2 ± 0.7%, respectively. Intermediate sizes were used in 39% (21.5 mm: 8%, 24.5 mm: 15%, 27.5 mm: 15%). There were no cases of valve embolization, coronary artery occlusion, annulus rupture, or procedural death. A definitive pacemaker implantation was needed in eight patients (8%). At 30-day follow-up aortic valve area (0.7 ± 0.2 vs. 2.1 ± 0.6 cm2) and mean aortic valve gradient (43.4 ± 11.1 vs. 9.0 ± 3.7 mmHg) improved significantly (p < 0.001). Moderate aortic regurgitation occurred in 4%. Endpoints of early safety and clinical efficacy were 3 and 1%, respectively. Conclusions: Hemodynamic performance and 30-day clinical outcomes of the BE Myval THV in low-risk AS patients were favorable. Longer-term follow-up is warranted.
Published: 2021

17. Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak

Author: Solano-Lopez J, Luis Zamorano J, Sanz A, Amat-Santos I, Sarnago F, Ibanes E, Sanchis J, Blas J, Gomez-Hospital J, Martinez S, Maneiro-Melon N, Gaitan R, D'Gregorio J, Salido L, Mestre J, Sanmartin M, and Sanchez-Recalde A
Abstract: INTRODUCTION AND OBJECTIVES: Despite advances in treatment, patients with acute myocardial infarction (AMI) still exhibit unfavorable short- and long-term prognoses. In addition, there is scant evidence about the clinical outcomes of patients with AMI and coronavirus disease 2019 (COVID-19). The objective of this study was to describe the clinical presentation, complications, and risk factors for mortality in patients admitted for AMI during the COVID-19 pandemic.; METHODS: This prospective, multicenter, cohort study included all consecutive patients with AMI who underwent coronary angiography in a 30-day period corresponding chronologically with the COVID-19 outbreak (March 15 to April 15, 2020). Clinical presentations and outcomes were compared between COVID-19 and non-COVID-19 patients. The effect of COVID-19 on mortality was assessed by propensity score matching and with a multivariate logistic regression model.; RESULTS: In total, 187 patients were admitted for AMI, 111 with ST-segment elevation AMI and 76 with non-ST-segment elevation AMI. Of these, 32 (17%) were diagnosed with COVID-19. GRACE score, Killip-Kimball classification, and several inflammatory markers were significantly higher in COVID-19-positive patients. Total and cardiovascular mortality were also significantly higher in COVID-19-positive patients (25% vs 3.8% [P 140 (OR, 23.45; 95%CI, 2.52-62.51; P=.005) and COVID-19 (OR, 6.61; 95%CI, 1.82-24.43; P=.02) were independent predictors of in-hospital death.; CONCLUSIONS: During this pandemic, a high GRACE score and COVID-19 were independent risk factors associated with higher in-hospital mortality. Copyright © 2020 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
Published: 2020

18. [Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience]

Author: Rodriguez-Leor O, Cid-Alvarez B, Perez de Prado A, Rossello X, Serrador A, Lopez-Palop R, Martin-Moreiras J, Rumoroso J, Cequier A, Ibanez B, Cruz-Gonzalez I, Romaguera R, Moreno R, Villa M, Ruiz-Salmeron R, Molano F, Sanchez C, Munoz-Garcia E, Inigo L, Herrador J, Gomez-Menchero A, Caballero J, Ojeda S, Cardenas M, Gheorghe L, Oneto J, Morales F, Valencia F, Ruiz J, Diarte J, Avanzas P, Rondan J, Peral V, Pernasetti L, Hernandez J, Bosa F, Lorenzo P, Jimenez F, Jimenez-Mazuecos J, Lozano F, Moreu J, Novo E, Robles J, Moreiras J, Fernandez-Vazquez F, Amat-Santos I, Gomez-Hospital J, Garcia-Picart J, Blanco B, Regueiro A, Carrillo-Suarez X, Tizon H, Mohandes M, Casanova J, Agudelo-Montanez V, Munoz J, Franco J, Del Castillo R, Salinas P, Elizaga J, Sarnago F, Jimenez-Valero S, Rivero F, Oteo J, Alegria-Barrero E, Sanchez-Recalde A, Ruiz V, Pinar E, Planas A, Ledesma B, Berenguer A, Fernandez-Cisnal A, Aguar P, Pomar F, Jerez M, Torres F, Garcia R, Frutos A, Nodar J, Garcia K, Saez R, Torres A, Telleria M, Sadaba M, Minguez J, Merchan J, Portales J, Trillo R, Aldama G, Fernandez S, Santas M, Perez M, Working Group on the Infarct Code of the Interventional Cardiology, and Association of the Spanish Society of Cardiology Investigators
Abstract: INTRODUCTION AND OBJECTIVES: The COVID-19 outbreak has had an unclear impact on the treatment and outcomes of patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study was to assess changes in STEMI management during the COVID-19 outbreak. METHODS: Using a multicenter, nationwide, retrospective, observational registry of consecutive patients who were managed in 75 specific STEMI care centers in Spain, we compared patient and procedural characteristics and in-hospital outcomes in 2 different cohorts with 30-day follow-up according to whether the patients had been treated before or after COVID-19. RESULTS: Suspected STEMI patients treated in STEMI networks decreased by 27.6% and patients with confirmed STEMI fell from 1305 to 1009 (22.7%). There were no differences in reperfusion strategy (> 94% treated with primary percutaneous coronary intervention in both cohorts). Patients treated with primary percutaneous coronary intervention during the COVID-19 outbreak had a longer ischemic time (233 [150-375] vs 200 [140-332] minutes, P
Published: 2020

19. Sex differences in patients with ischemia and no obstructive coronary disease subjected to intracoronary acetylcholine test in a multicenter registry

Author: Grigorian, L, primary, Gutierrez, E, additional, Oteo, J.F, additional, Abdul-Jawad, O, additional, Amat Santos, I, additional, Gutierrez Barrios, A, additional, Fernandez Cisnal, A, additional, Jimenez Mazuecos, J, additional, Roa, J, additional, Vazquez, M.E, additional, Sanz, R, additional, Diez-Delhoyo, F, additional, Rivera, A, additional, Elizaga, J, additional, and Fernandez-Aviles, F, additional
Published: 2020
Full Text: View/download PDF

20. Clinical profile and predictors of positivity of acetylcholine test in patients with angina and no obstructive coronary artery disease. Results of a multi-center mediterranean registry

Author: Grigorian, L, primary, Gutierrez, E, additional, Oteo, J.F, additional, Abdul-Jawad, O, additional, Amat Santos, I, additional, Gutierrez Barrios, A, additional, Fernandez Cisnal, A, additional, Jimenez Mazuecos, J, additional, Roa, J, additional, Vazquez, M.E, additional, Sanz, R, additional, Diez-Delhoyo, F, additional, Rivera, A, additional, Elizaga, J, additional, and Fernandez-Aviles, F, additional
Published: 2020
Full Text: View/download PDF

21. 3 Impact of morbid obesity and obesity phenotype on outcomes post transcatheter aortic valve replacement

Author: McInerney, A, primary, Tirado-Conte, G, additional, Rodes-Cabau, J, additional, Campelo-Parada, F, additional, Tafur Soto, JD, additional, Barbanti, M, additional, Muñoz-Garcia, E, additional, Arif, M, additional, Lopez, D, additional, Toggweiler, S, additional, Veiga, G, additional, Pylko, A, additional, Sevilla, T, additional, Compagnone, M, additional, Regueiro, A, additional, Serra, V, additional, Carnero, M, additional, Oteo, JF, additional, Rivero, F, additional, Barbosa Ribeiro, H, additional, Guimaraes, L, additional, Matta, A, additional, Giraldo Echavarria, N, additional, Valvo, R, additional, Moccetti, F, additional, Muñoz-Garcia, AJ, additional, Lopez-Pais, J, additional, Garcia del Blanco, B, additional, Carter Campanha Borges, D, additional, Gonzalo, N, additional, Dumont, E, additional, Criscione, E, additional, Dabrowski, M, additional, Alfonso, F, additional, de la Torre Hernández, JM, additional, Cheema, AN, additional, Amat-Santos, I, additional, Saia, F, additional, Escaned, J, additional, and Nombela-Franco, L, additional
Published: 2020
Full Text: View/download PDF

22. LASER CORONARY ATHERECTOMY AND POLYMERIC CORONARY WIRES IN UNCROSSABLE LESIONS – A WORD OF CAUTION

Author: Marengo, G, Amat Santos, I, De Benedictis, M, Barbero, U, Doronzo, M, and Moncalvo, C
Published: 2024
Full Text: View/download PDF

23. VALIDATION OF QUANTITATIVE FLOW RATIO DERIVED VIRTUAL ANGIOPLASTY WITH POST–ANGIOPLASTY FRACTIONAL FLOW RESERVE. THE QIMERA–I STUDY

Author: Marengo, G, Amat Santos, I, Cortes Villar, C, Doronzo, M, De Benedictis, M, Barbero, U, and Moncalvo, C
Published: 2024
Full Text: View/download PDF

24. P1962Impact of Dual Antiplatelet Therapy duration on clinical outcome after stent implantation for coronary bifurcation lesions: results from the Euro Bifurcation Club - P2BiTO - registry

Author: Di Serafino, L, primary, Gamra, H, additional, Cirillo, P, additional, Zimarino, M, additional, Amat-Santos, I J, additional, Barbato, E, additional, Briguori, C, additional, Chieffo, A, additional, Ergilis, A, additional, Gil, R J, additional, Kedev, S A, additional, Petrov, I, additional, Radico, F, additional, Nakamura, S, additional, and Stankovic, G, additional
Published: 2019
Full Text: View/download PDF

25. P871Coronary artery aneurysms: clinical features, management and long-term outcomes, insights from the international coronary artery aneurysm registry (CAAR)

Author: Nunez-Gil, I, primary, Cerrato, E, additional, Bollati, M, additional, Nombela-Franco, L, additional, Alfonso, E, additional, Camacho Freire, S, additional, Villablanca, P, additional, Amat Santos, I, additional, De La Torre Hernandez, J M, additional, Pascual, I, additional, Liebetrau, C, additional, Camacho, B, additional, Pavani, M, additional, Feltes, G, additional, and Fernandez Ortiz, A, additional
Published: 2019
Full Text: View/download PDF

26. Predictors and impact of myocardial injury after transcatheter aortic valve replacement: a multicenter registry

Author: Ribeiro HB, Nombela-Franco L, Munoz-Garcia AJ, Lemos PA, Amat-Santos I, Serra V, de Brito FS, Jr., Abizaid A, Sarmento-Leite R, Puri R, Cheema AN, Ruel M, Nietlispach F, Maisano F, Moris C, Del Valle R, Urena M, Abdul Jawad Altisent O, Del Trigo M, Campelo-Parada F, Jimenez Quevedo P, Alonso-Briales JH, Gutierrez H, Garcia Del Blanco B, Perin MA, Siqueira D, Bernardi G, Dumont E, Cote M, Pibarot P, Rodes-Cabau J, Ribeiro, Hb, Nombela-Franco, L, Munoz-Garcia, Aj, Lemos, Pa, Amat-Santos, I, Serra, V, de Brito, F, J, R., Abizaid, A, Sarmento-Leite, R, Puri, R, Cheema, An, Ruel, M, Nietlispach, F, Maisano, F, Moris, C, Del Valle, R, Urena, M, Abdul Jawad Altisent, O, Del Trigo, M, Campelo-Parada, F, Jimenez Quevedo, P, Alonso-Briales, Jh, Gutierrez, H, Garcia Del Blanco, B, Perin, Ma, Siqueira, D, Bernardi, G, Dumont, E, Cote, M, Pibarot, P, and Rodes-Cabau, J
Published: 2015

27. 4282Validation of the “multivalvular score” for the assessment of patients with concomitant mitral and aortic valve disease under evaluation for transcatheter aortic valve implantation

Author: Amat Santos, I J, primary, Catala, P, additional, Aparisi, A, additional, Cortes, C, additional, Goncalves Ramirez, L R, additional, Gutierrez Garcia, H, additional, Ramos, B, additional, Serrador, A, additional, Vera, S, additional, Revilla Orodea, A, additional, Gomez, I, additional, Carrasco Moraleja, M, additional, and San Roman Calvar, J A, additional
Published: 2018
Full Text: View/download PDF

28. P4625Functional evolution of non-culprit lesions in acute myocardial infarction. A quantitative flow ratio study

Author: Cortes Villar, C, primary, Vera Vera, S, additional, Goncalves, L R, additional, Ramos, B, additional, Serrador, A, additional, Gutierrez, H, additional, Carrasco, M, additional, Gomez, I, additional, San Roman, J A, additional, and Amat-Santos, I J, additional
Published: 2018
Full Text: View/download PDF

29. P4637A simplified formula to calculate fractional flow reserve in sequential lesions circumventing the measurement of coronary wedge pressure during balloon inflation: the APIS-S pilot study

Author: Cortes Villar, C, primary, Jaguszewski, M, additional, Schincariol, M, additional, Amat-Santos, I J, additional, Franco-Pelaez, J A, additional, Ciecwierz, D, additional, Wojakowski, W, additional, Navarro, F, additional, Mischke, K, additional, San Roman, J A, additional, Ibanez, B, additional, and Gutierrez-Chico, J L, additional
Published: 2018
Full Text: View/download PDF

30. TCT-90 Predictive Factors and Long-Term Clinical Consequences of Persistent Left Bundle Branch Block Following Transcatheter Aortic Valve Implantation with a Balloon-Expandable Valve

Author: Urena, M, Mok, Michael, Serra, V, Dumont, E, Nombela-Franco, L, De Larochelliere, R, Doyle, D, Igual, A, Larose, E, Amat-Santos, I, Coté, M, Cuellar, H, Pibarot, P, De Jaegere, P, Philippon, F, Blanco, BGD, Rodes-Cabau, J, Urena, M, Mok, Michael, Serra, V, Dumont, E, Nombela-Franco, L, De Larochelliere, R, Doyle, D, Igual, A, Larose, E, Amat-Santos, I, Coté, M, Cuellar, H, Pibarot, P, De Jaegere, P, Philippon, F, Blanco, BGD, and Rodes-Cabau, J
Published: 2012

31. Importance of size and circumferential shape of the aortic annulus assesed with computed tomography to determine post-TAVI aortic regurgitation

Author: Amat Santos, I. J., primary, Revilla Orodea, A., additional, Lopez Diaz, J., additional, Hernandez Luis, C., additional, Cortes Villar, C., additional, Gimeno De Carlos, F., additional, Gutierrez Garcia, H., additional, Serrador Frutos, A. M., additional, Puerto Sanz, A., additional, and San Roman Calvar, J. A., additional
Published: 2013
Full Text: View/download PDF

32. Poster session IV * Friday 10 December 2010, 14:00-18:00

Author: Mora, B., primary, Base, E., additional, Schmid, W., additional, Andreas, M., additional, Weber, U., additional, Junreitmaier, M., additional, Foerster, F., additional, Hiesmayr, M., additional, Tschernich, H. D., additional, Guldbrand, D., additional, Goetzsche, O., additional, Eika, B., additional, Fumagalli, S., additional, Francini, S., additional, Gabbai, D., additional, Pedri, S., additional, Casalone Rinaldi, M., additional, Makhanian, Y., additional, Sollami, R., additional, Tarantini, F., additional, Marchionni, N., additional, Azcarate, P. M., additional, Castano, S., additional, Rodriguez-Manero, M., additional, Arraiza, M., additional, Levy, B., additional, Barba, J., additional, Rabago, G., additional, Bastarrika, G., additional, Rus, H., additional, Radoi, M., additional, Ciurea, C., additional, Boda, D., additional, Erdei, T., additional, Denes, M., additional, Mihalcz, A., additional, Kardos, A., additional, Foldesi, C. S., additional, Temesvari, A., additional, Lengyel, M., additional, Cameli, M., additional, Lisi, M., additional, Righini, F., additional, Ballo, P., additional, Henein, M., additional, Mondillo, S., additional, Nistri, S., additional, Galderisi, M., additional, Ballo, P. C., additional, Pagliani, L., additional, Olivotto, I., additional, Santoro, A., additional, Papesso, B., additional, Innelli, P., additional, Cecchi, F., additional, Hristova, K., additional, Katova, T. Z., additional, Kostova, V., additional, Simova, Y., additional, Nesheva, N., additional, Ivanovic, B., additional, Tadic, M. T., additional, Simic, D. S., additional, Rao, C. M., additional, Aguglia, D., additional, Casciola, G., additional, Imbesi, C., additional, Marvelli, A., additional, Sgro, M., additional, Benedetto, D., additional, Tripepi, G., additional, Zoccali, C., additional, Benedetto, F. A., additional, Mantziari, L., additional, Kamperidis, V., additional, Damvopoulou, E., additional, Ventoulis, I., additional, Giannakoulas, G., additional, Paraskevaidis, S., additional, Vassilikos, V., additional, Karvounis, H., additional, Styliadis, I. H., additional, Sonder, T. K., additional, Loegstrup, B. B., additional, Lambrechtsen, J., additional, Van Bortel, L. M., additional, Segers, P., additional, Egstrup, K., additional, Tho, A., additional, Moceri, P., additional, Bertora, D., additional, Gibelin, P., additional, Cho, E. J., additional, Choi, K. Y., additional, Kim, B. J., additional, Kim, D. B., additional, Jang, S. W., additional, Park, C. S., additional, Jung, H. O., additional, Jeon, H. K., additional, Youn, H. J., additional, Kim, J. H., additional, Donal, E., additional, Coquerel, N., additional, Bodi, S., additional, Thebault, C., additional, Kervio, G., additional, Carre, F., additional, Daly, M. J., additional, Fairley, S. L., additional, Doherty, R., additional, Ashfield, K., additional, Kirkpatrick, R., additional, Smith, B., additional, Buchanan, J., additional, Hill, L., additional, Dixon, L. J., additional, Rosca, M., additional, O' Connor, K., additional, Magne, J., additional, Romano, G., additional, Calin, A., additional, Popescu, B. A., additional, Beladan, C. C., additional, Pierard, L., additional, Ginghina, C., additional, Lancellotti, P., additional, Bochenek, T., additional, Wita, K., additional, Tabor, Z., additional, Grabka, M., additional, Elzbieciak, M., additional, Trusz-Gluza, M., additional, Moreau, O., additional, Leclercq, C., additional, Sahlen, A., additional, Shahgaldi, K., additional, Aminoff, A., additional, Aagaard, P., additional, Manouras, A., additional, Winter, R., additional, Ehrenborg, E., additional, Braunschweig, F., additional, Bedetti, G., additional, Gargani, L., additional, Pizzi, C., additional, Sicari, R., additional, Picano, E., additional, Zhang, J., additional, Zhang, H. B., additional, Duan, Y. Y., additional, Chen, L. L., additional, Li, J., additional, Liu, L. W., additional, Zhu, T., additional, Li, H. L., additional, Su, H. L., additional, Zhou, X. D., additional, Ruiz Ortiz, M., additional, Mesa Rubio, D., additional, Delgado Ortega, M., additional, Romo Penas, E., additional, Toledano Degado, F., additional, Leon Del Pino, C., additional, Lopez Aguilera, J., additional, Villanueva Fernandez, E., additional, Cejudo Diaz Del Campo, L., additional, Suarez De Lezo, J., additional, Abergel, E., additional, Simon, M., additional, Dehant, P., additional, Bogino, E., additional, Jimenez, M., additional, Verdier, J. C., additional, Chauvel, C., additional, Albertsen, A. E., additional, Nielsen, J. C., additional, Mortensen, P. T., additional, Egeblad, H., additional, Nasr, G. M., additional, Tawfik, S., additional, Omar, A., additional, Olofsson, M., additional, Boman, K., additional, Rezzoug, N., additional, Vaes, B., additional, Degryse, J., additional, Vanoverschelde, J.-L., additional, Pasquet, A. A., additional, Poggio, D., additional, Bonadies, M., additional, Pacher, V., additional, Mazzetti, S., additional, Grillo, M., additional, D'elia, E., additional, Khouri, T., additional, Specchia, G., additional, Mornos, C., additional, Rusinaru, D., additional, Cozma, D., additional, Ionac, A., additional, Petrescu, L., additional, Rotzak, R., additional, Rosenman, Y., additional, Patterson, R. D., additional, Ratnatheepan, S., additional, Bogle, R. G., additional, Goebel, B., additional, Gjesdal, O., additional, Kottke, D., additional, Otto, S., additional, Jung, C., additional, Edvardsen, T., additional, Figulla, H. R., additional, Poerner, T. C., additional, Otsuka, T., additional, Suzuki, M., additional, Yoshikawa, H., additional, Hashimoto, G., additional, Itou, N., additional, Ono, T., additional, Yamamoto, M., additional, Osaki, T., additional, Tsuchida, T., additional, Sugi, K., additional, Wolber, T., additional, Haegeli, L., additional, Huerlimann, D., additional, Brunckhorst, C., additional, Duru, F., additional, Wu, Z. M., additional, Shu, X. H., additional, Dong, L. L., additional, Fan, B., additional, Ge, J. B., additional, Greutmann, M., additional, Tobler, D., additional, Biaggi, P., additional, Mah, M., additional, Crean, A., additional, Oechslin, E. N., additional, Silversides, C. K., additional, Giusca, S., additional, Jurcut, R., additional, Ghiorghiu, I., additional, Coman, I. M., additional, Amzulescu, M., additional, Ionescu, R., additional, Delcroix, M., additional, Voigt, J. U., additional, Piatkowski, R., additional, Kochanowski, J., additional, Scislo, P., additional, Grabowski, M., additional, Marchel, M., additional, Roik, M., additional, Kosior, D., additional, Opolski, G., additional, Maceira Gonzalez, A. M., additional, Cosin-Sales, J., additional, Dalli, E., additional, Igual, B., additional, Monmeneu, J. V., additional, Lopez-Lereu, P., additional, Estornell, J., additional, Ruvira, J., additional, Sotillo, J., additional, Stevanovic, A., additional, Toncev, A., additional, Dimkovic, S., additional, Dekleva, M., additional, Paunovic, N., additional, Toncev, D., additional, Sekularac, N., additional, Yildirimturk, O., additional, Helvacioglu, F. F., additional, Tayyareci, Y., additional, Yurdakul, S., additional, Demiroglu, I. C. C., additional, Aytekin, S., additional, Pinedo Gago, M., additional, Amat Santos, I., additional, Revilla Orodea, A., additional, Lopez Diaz, J., additional, Arnold, R., additional, De La Fuente Galan, L., additional, Recio Platero, A., additional, Gomez Salvador, I., additional, Puerto Sanz, A., additional, San Roman Calvar, J. A., additional, Yotti, R., additional, Bermejo, J., additional, Mombiela, T., additional, Benito, Y., additional, Sanchez, P. L., additional, Solis, J., additional, Prieto, R., additional, Fernandez-Aviles, F., additional, Zilberszac, R., additional, Gabriel, H., additional, Graf, S., additional, Mundigler, G., additional, Maurer, G., additional, Rosenhek, R., additional, Zito, C., additional, Salvia, J., additional, Longordo, C., additional, Donato, D., additional, Alati, E., additional, Miceli, M., additional, Pardeo, A., additional, Arcidiaco, S., additional, Oreto, G., additional, Carerj, S., additional, Hadjimiltiades, S., additional, Sianos, G., additional, Anastasiadis, K., additional, Grosomanidis, V., additional, Efthimiadis, G., additional, Parcharidis, G., additional, Yousry, M., additional, Rickenlund, A., additional, Petrini, J., additional, Gustafsson, T., additional, Liska, J., additional, Hamsten, A., additional, Eriksson, P., additional, Franco-Cereceda, A., additional, Eriksson, M. J., additional, Caidahl, K., additional, Mizia-Stec, K., additional, Pysz, P., additional, Jasinski, M., additional, Drzewiecka-Gerber, A., additional, Krejca, M., additional, Bochenek, A., additional, Wos, S., additional, Gasior, Z., additional, Tendera, M., additional, Niki, K., additional, Sugawara, M., additional, Takamisawa, I., additional, Watanabe, H., additional, Sumiyoshi, T., additional, Hosoda, S., additional, Ida, T., additional, Takanashi, S., additional, Olsen, N. T., additional, Sogaard, P., additional, Jons, C., additional, Mogelvang, R., additional, Larsson, H. B. W., additional, Goetze, J. P., additional, Nielsen, O. W., additional, Fritz-Hansen, T., additional, Sayar, N., additional, Orhan, A. L., additional, Erer, H. B., additional, Eren, M., additional, Atmaca, H., additional, Yilmaz, H. Y., additional, Cakmak, N., additional, Altay, S., additional, Terzi, S., additional, Yesilcimen, K., additional, Garcia Orta, R., additional, Moreno, E., additional, Lopez, M., additional, Uribe, I., additional, Vidal, M., additional, Ruiz-Lopez, M. F., additional, Gonzalez-Molina, M., additional, Oyonarte, J. M., additional, Lopez, S., additional, Azpitarte, J., additional, Szymanski, C., additional, Levine, R. A., additional, Zheng, H., additional, Handschumacher, M. D., additional, Tawakol, A., additional, Hung, J., additional, Le Ven, F., additional, Etienne, Y., additional, Jobic, Y., additional, Frachon, I., additional, Castellant, P., additional, Fatemi, M., additional, Blanc, J. J., additional, Tribouilloy, C., additional, Grigioni, F., additional, Avierinos, J.-F., additional, Barbieri, A., additional, Buiciuc, O., additional, Enriquez-Sarano, M., additional, Said, K., additional, Farag, A. K., additional, El-Ramly, M., additional, Rizk, H., additional, Iorio, A., additional, Pinamonti, B., additional, Bobbo, M., additional, Merlo, M., additional, Massa, L., additional, Faganello, G., additional, Di Lenarda, A., additional, Sinagra, G., additional, Margato, R., additional, Ribeiro, H., additional, Ferreira, C., additional, Matias, A., additional, Fontes, P., additional, Moreira, J. I., additional, Milan, A., additional, Puglisi, E., additional, Magnino, C., additional, Fabbri, A., additional, Leone, D., additional, Vairo, A., additional, Crudo, V., additional, Iannaccone, A., additional, Milazzo, V., additional, Veglio, F., additional, Maroz-Vadalazhskaya, N., additional, Ostrovskiy, I., additional, Imbalzano, E., additional, Saitta, A., additional, Cusma-Piccione, M., additional, Di Bella, G., additional, Nava, R., additional, Ferro, M., additional, Falanga, G., additional, Frigy, A., additional, Buzogany, J., additional, Szabados, C. S., additional, Dan, L., additional, Carasca, E., additional, Ikonomidis, I., additional, Lekakis, J., additional, Tzortzis, S., additional, Kremastinos, D. T., additional, Papadopoulos, C., additional, Paraskevaidis, I., additional, Triantafyllidi, H., additional, Trivilou, P., additional, Venetsanou, K., additional, Anastasiou-Nana, M., additional, Wierzbowska-Drabik, K., additional, Kurpesa, M., additional, Trzos, E., additional, Rechcinski, T., additional, Mozdzan, M., additional, Kasprzak, J. D., additional, Kosmala, W., additional, Kotwica, T., additional, Przewlocka-Kosmala, M., additional, Mysiak, A., additional, Skultetyova, D., additional, Filipova, S., additional, Chnupa, P., additional, Pechlivanidis, G., additional, Dimitroula, H., additional, Tsai, W.-C., additional, Liu, Y.-W., additional, Lin, C.-C., additional, Huang, Y.-Y., additional, Tsai, L.-M., additional, Park, S. M., additional, Kim, Y. H., additional, Shin, S. M., additional, Shim, W. J., additional, Gonzalez Mansilla, A., additional, Torres Macho, J., additional, Sanchez Sanchez, V., additional, Diez, P., additional, Delgado, J., additional, Borruel, S., additional, Saenz De La Calzada, C., additional, Pyxaras, S., additional, Valentincic, M., additional, Barbati, G., additional, Lo Giudice, F., additional, Perkan, A., additional, Magnani, S., additional, Palecek, T., additional, Ambroz, D., additional, Jansa, P., additional, Lindner, J., additional, Vitovec, M., additional, Polacek, P., additional, Jiratova, K., additional, Linhart, A., additional, Baskurt, M., additional, Dogan, G. M., additional, Abaci, O., additional, Kaya, A., additional, Kucukoglu, S., additional, Duszanska, A., additional, Kukulski, T., additional, Skoczylas, I., additional, Majsnerowska, A., additional, Nowowiejska-Wiewiora, A., additional, Streb, W., additional, Szulik, M., additional, Polonski, L., additional, Kalarus, Z., additional, Yerly, P. O., additional, Prella, M., additional, Joly, A., additional, Nicod, L., additional, Aubert, J. D., additional, Aebischer, N., additional, Dores, H., additional, Leal, S., additional, Rosario, I., additional, Correia, M. J., additional, Monge, J., additional, Grilo, A. M., additional, Arroja, I., additional, Fonseca, C., additional, Aleixo, A., additional, Silva, A., additional, Perez-David, E., additional, Sanchez-Alegre, M., additional, Gomez Anta, I., additional, De La Torre, J., additional, Alarcon, J., additional, Garcia Robles, J. A., additional, Lafuente, J., additional, Garcia Alonso, C. J., additional, Vallejo Camazon, N., additional, Gonzalez Guardia, A., additional, Nunez, R., additional, Bosch Carabante, C., additional, Mateu, L., additional, Gual Capllonch, F., additional, Ferrer Sistach, E., additional, Lopez Ayerbe, J., additional, Bayes Genis, A., additional, Tomaszewski, A., additional, Kutarski, A., additional, Tomaszewski, M., additional, Bramos, D., additional, Kalantaridou, A., additional, Takos, D., additional, Skaltsiotis, E., additional, Trika, C., additional, Tsirikos, N., additional, Pamboukas, C., additional, Kottis, G., additional, Toumanidis, S., additional, Aggeli, C., additional, Felekos, I., additional, Roussakis, G., additional, Kazazaki, C., additional, Lampropoulos, K., additional, Lagoudakou, S., additional, Stergiou, C., additional, Pitsavos, C., additional, Stefanadis, C., additional, Kihara, C., additional, Murata, K., additional, Wada, Y., additional, Tanaka, T., additional, Uchida, K., additional, Okuda, S., additional, Susa, T., additional, Matsuzaki, M., additional, Abrahamsson, A., additional, Gudmundsson, P., additional, Brodin, L., additional, Knebel, F., additional, Schattke, S., additional, Sanad, W., additional, Schimke, I., additional, Schroeckh, S., additional, Brechtel, L., additional, Lock, J., additional, Makauskiene, R., additional, Baumann, G., additional, Borges, A. C., additional, Moelmen-Hansen, H. E., additional, Wisloff, U., additional, Aamot, I. L., additional, Stoylen, A., additional, Ingul, C. B., additional, Estensen, M.-E., additional, Beitnes, J. O., additional, Grindheim, G., additional, Henriksen, T., additional, Aaberge, L., additional, Smiseth, O. A., additional, Gullestad, L., additional, Aakhus, S., additional, Agoston, G., additional, Moggi Pignone, A., additional, Capati, E., additional, Badano, L., additional, Moreo, A., additional, Bombardieri, S., additional, Varga, A., additional, Carrideo, M., additional, Faricelli, S., additional, Corazzini, A., additional, Ippedico, R., additional, Ruggieri, B., additional, Di Blasio, A., additional, D'angelo, E., additional, Di Baldassarre, A., additional, Ripari, P., additional, Gallina, S., additional, Kentrschynskyj, A., additional, Hylander, B., additional, Jacobson, S., additional, Pagels, A., additional, Dumitrescu, S. I., additional, Tintoiu, I., additional, Greere, V., additional, Cristian, G., additional, Chiriac, L., additional, Pinte, F., additional, Droc, I., additional, Neagoe, G., additional, Stanciu, S., additional, Voicu, V. A., additional, Kuch-Wocial, A., additional, Pruszczyk, P., additional, Szmigielski, C. A., additional, Szulc, M., additional, Styczynski, G., additional, Sinski, M., additional, Kaczynska, A., additional, Ryabikov, A., additional, Malyutina, S., additional, Halcox, J., additional, Bobak, M., additional, Nikitin, Y. U., additional, Marmot, M., additional, Barbosa, D., additional, Kiss, G., additional, Orderud, F., additional, Amundsen, B., additional, Jasaityte, R., additional, Loeckx, D., additional, Claus, P., additional, Torp, H., additional, D'hooge, J., additional, Kuhl, J. T., additional, Lonborg, J., additional, Fuchs, A., additional, Andersen, M., additional, Vejlstrup, N., additional, Engstrom, T., additional, Moller, J. E., additional, Kofoed, K. F., additional, Smith, L. A., additional, Bhan, A., additional, Paul, M., additional, Monaghan, M. J., additional, Zaborska, B., additional, Stec, S., additional, Sikora-Frac, M., additional, Krynski, T., additional, Kulakowski, P., additional, Pushparajah, K., additional, Dashwood, D., additional, Barlow, A., additional, Nugent, K., additional, Miller, O., additional, Simpson, J., additional, Valeur, N., additional, Ersboll, M. K., additional, Kjaergaard, J., additional, Greibe, R., additional, Risum, N., additional, Hassager, C., additional, Kober, L., additional, Popovic, D., additional, Nedeljkovic, I., additional, Petrovic, M., additional, Vujisic-Tesic, B., additional, Arandjelovic, A., additional, Stojiljkovic, S., additional, Jakovljevic, B., additional, Damjanovic, S., additional, Ostojic, M., additional, Agrios, I. A., additional, Bramos, D. B., additional, Skaltsiotis, H. S., additional, Takos, D. T., additional, Kaladaridis, A., additional, Vasiladiotis, N. V., additional, Kottis, G. K., additional, Antoniou, A. A., additional, Pamboucas, C. P., additional, Toumanidis, S. T. T., additional, Locorotondo, G., additional, Porto, I., additional, Paraggio, L., additional, Fedele, E., additional, Barchetta, S., additional, De Caterina, A. R., additional, Rebuzzi, A. G., additional, Crea, F., additional, Galiuto, L., additional, Lipiec, P., additional, Szymczyk, E., additional, Michalski, B., additional, Wozniakowski, B., additional, Stefanczyk, L., additional, Rotkiewicz, A., additional, Shim, A., additional, Vainer, J., additional, Habets, J., additional, Lousberg, A., additional, Pont De, C., additional, Waltenberger, J., additional, Farouk, H., additional, Heshmat, H., additional, Adel, A., additional, El Chilali, K., additional, Baghdady, Y., additional, Sorour, K., additional, Gustafsson, U., additional, Larsson, M., additional, Bjallmark, A., additional, Lindqvist, P., additional, A'roch, R., additional, Haney, M., additional, Waldenstrom, A., additional, Mladenovic, Z., additional, Tavciovski, D., additional, Mijailovic, Z., additional, Djordjevic - Dikic, A., additional, Obradovic, S., additional, Matunovic, R., additional, Jovic, Z., additional, Djuric, P., additional, Aase, S., additional, Dalen, H., additional, Sarkola, T., additional, Redington, A. N., additional, Keeley, F., additional, Bradley, T., additional, Jaeggi, E., additional, and Sahlen, H., additional
Published: 2010
Full Text: View/download PDF

33. Abstracts

Author: Barthelemy, O., primary, Silvain, J., additional, Brieger, D., additional, Bellemain-Appaix, A., additional, Cayla, G., additional, Beygui, F., additional, Lancar, R., additional, Collet, J. P., additional, Mercadier, A., additional, Montalescot, G., additional, Cha, K. S., additional, Nam, Y. H., additional, Kim, J. H., additional, Park, S. Y., additional, Park, T. H., additional, Kim, M. H., additional, Kim, Y. D., additional, Lee, H. C., additional, Ahn, M. S., additional, Hong, T. J., additional, Blanco, R., additional, Blanco, F., additional, Szarfer, J., additional, Garcia Escudero, A., additional, Gigena, G., additional, Gagliardi, J., additional, Rodriguez, A., additional, Sarmiento, R., additional, Affatatto, S., additional, Riccitelli, M., additional, Petris, A., additional, Datcu, M. D., additional, Pop, C., additional, Radoi, M., additional, Arsenescu-Georgescu, C., additional, Petrescu, I., additional, Petrescu, L., additional, Serban, L., additional, Nechita, E., additional, Tatu-Chitoiu, G., additional, Dorobantu, M., additional, Benedek, I., additional, Craiu, E., additional, Sinescu, C., additional, Ionescu, D. D., additional, Ginghina, C., additional, Minescu, B., additional, Izzo, A., additional, Mantovani, P., additional, Tomasi, L., additional, Dall'oglio, L., additional, Bonatti, S., additional, Rosiello, R., additional, Romano, M., additional, Agostini, F., additional, Zanini, R., additional, Zhao, Z. Y., additional, Wu, Y. J., additional, Li, J. J., additional, Yany, Y. J., additional, Qian, H. Y., additional, Tang, Y. D., additional, Timoteo, A. T., additional, Toste, A., additional, Lousinha, A., additional, Ramos, R., additional, Oliveira, J. A., additional, Ferreira, M. L., additional, Ferreira, R. C., additional, Cabades, C., additional, Diez Gil, J. L., additional, Aguar, P., additional, Sanmiguel, D., additional, Lopez-March, A., additional, Marmol, R., additional, Guerra, L., additional, Girbes, V., additional, Ferrando, J., additional, Rincon De Arellano, A., additional, Patricio, L., additional, Blondal, M., additional, Ainla, T., additional, Marandi, T., additional, Eha, J., additional, Oliveira, M. M., additional, Silva, M. N., additional, Cunha, P. S., additional, Feliciano, J., additional, Silva, S., additional, Kanovsky, J., additional, Kala, P., additional, Parenica, J., additional, Poloczek, M., additional, Prymusova, K., additional, Kubkova, L., additional, Spinar, J., additional, Olinic, D., additional, Homorodean, C., additional, Ober, M., additional, Olinic, M., additional, Andrioaia, C., additional, Condac, A., additional, Masmoudi, M., additional, Berdaoui, B., additional, Labidi, S., additional, Tapia Ballesteros, C., additional, Hernandez Luis, C., additional, Sandin, M. G., additional, Vegas, J. M., additional, Andion, R., additional, Martinez, N., additional, Gonzalez, I. A., additional, Alvarado, M., additional, Amat, I. J., additional, San Roman, J. A., additional, Garcia Gonzalez, M. J., additional, Arroyo Ucar, E., additional, Hernandez Garcia, C., additional, Dorta Martin, M., additional, Marrero Rodriguez, F., additional, Dragu, R., additional, Kapeliovich, M., additional, Hammerman, H., additional, Silva, D., additional, Cortez-Dias, N., additional, Jorge, C., additional, Silva Marques, J., additional, Carilho Ferreira, P., additional, Robalo Martins, S., additional, Almeida Ribeiro, M., additional, Calisto, C., additional, Fiuza, M., additional, Lopes, M. G., additional, Milicevic, P., additional, Panic, M., additional, Stankovic, I., additional, Milicevic, D., additional, Kalezic, T., additional, Kafedzic, S., additional, Ilic, I., additional, Cerovic, M., additional, Putnikovic, B., additional, Neskovic, A., additional, Rott, D., additional, Leibowitz, D., additional, Monhart, Z., additional, Reissigova, J., additional, Grunfeldova, H., additional, Jansky, P., additional, Valente, B., additional, Villanueva Benito, I., additional, Solla, I., additional, Paredes, E., additional, Diaz Castro, O., additional, Calvo, F., additional, Baz, J. A., additional, Iniguez, A., additional, Aleksova, A., additional, Gerloni, R., additional, Belfiore, R., additional, Carriere, C., additional, Barbati, G., additional, Fabris, E., additional, Possa, F., additional, Nait, D., additional, Milo, M., additional, Sinagra, G., additional, Marques, N., additional, Mimoso, J., additional, Gomes, V., additional, Agra Bermejo, R. M., additional, Emad Abu Assi, E. A. A., additional, Sergio Raposeiras Roubin, S. R. R., additional, Pilar Cabanas Grandio, P. C. G., additional, Carlos Pena Gil, C. P. G., additional, Jose Maria Garcia Acuna, J. M. G. A., additional, Jose Ramon Gonzalez Juanatey, J. R. G. J., additional, Daly, M. J., additional, Scott, P., additional, Owens, C. G., additional, Tomlin, A., additional, Smith, B., additional, Adgey, A. A. J., additional, Alvarez-Contreras, L. R., additional, Juarez, U., additional, Altamirano, A., additional, Arias, A., additional, Alvarez-San Gabriel, A., additional, Gonzalez-Pacheco, H., additional, Martinez-Sanchez, C., additional, Rahnavardi, M., additional, Keshtkar-Jahromi, M., additional, Vakili, H., additional, Gholamin, S., additional, Razavi, S. M., additional, Gilis-Januszewski, T., additional, Mellwig, K.- P., additional, Wiemer, M., additional, Gilis-Januszewski, J., additional, Peterschroeder, A., additional, Koerfer, J., additional, Horstkotte, D., additional, Vrsalovic, M., additional, Getaldic, B., additional, Vrkic, N., additional, Pintaric, H., additional, Khan, S., additional, Wasan, B., additional, Moretti, L., additional, Grossi, P., additional, Silenzi, S., additional, Testa, M., additional, Candelori, L., additional, Clementi, L. N., additional, Forlini, M., additional, Lando, L., additional, Pezzuoli, M. L., additional, Corradetti, P., additional, Leurent, G., additional, Pennec, P. Y., additional, Filippi, E., additional, Moquet, B., additional, Hacot, J. P., additional, Druelles, P., additional, Rialan, A., additional, Rouault, G., additional, Coudert, I., additional, Le Breton, H., additional, Gevaert, S., additional, Tromp, F., additional, Vandecasteele, E., additional, De Somer, F., additional, Van Belleghem, Y., additional, Bouchez, S., additional, Martens, F., additional, Herck, I., additional, De Pauw, M., additional, Ludka, O., additional, Sepsi, M., additional, Miklik, R., additional, Dusek, L., additional, Tomcikova, D., additional, Garcia-Acuna, J. M., additional, Aguiar-Souto, P., additional, Raposeiras Roubin, S., additional, Agra-Bermejo, R., additional, Jacquet, M., additional, Abu-Assi, E., additional, Gonzalez-Juanatey, J. R., additional, Ibatov, A., additional, Labrova, R., additional, Karlik, R., additional, Lokaj, P., additional, She, Q., additional, Deng, S. B., additional, Huang, S. H., additional, Gu, L. J., additional, Rong, J. I. A. N., additional, Wu, Z. K., additional, Li, Y., additional, Zhang, J., additional, Parascan, L., additional, Campanile, A., additional, Spinelli, L., additional, Santulli, G., additional, Ciccarelli, M., additional, De Gennaro, S., additional, Assante Di Panzillo, E., additional, Trimarco, B., additional, Iaccarino, G., additional, Bobescu, E., additional, Datcu, G., additional, Dobreanu, D., additional, Doka, B., additional, Charniot, J.- C., additional, Cosson, C., additional, Albertini, J. P., additional, Bittar, R., additional, Giral, P., additional, Cherfils, C., additional, Guillerm, E., additional, Bonnefont-Rousselot, D., additional, Rusali, A., additional, Cojocaru, L., additional, Parepa, I., additional, Koizumi, T., additional, Iida, S., additional, Sato, J., additional, Kikutani, T., additional, Muramatsu, T., additional, Nishimura, S., additional, Komiyama, N., additional, Lee, W. P., additional, Ong, B. B., additional, Haralambos, K., additional, Townsend, D., additional, Rees, J. A. E., additional, Williams, E. J., additional, Halcox, J. P., additional, Mcdowell, I., additional, Damjanovic, M., additional, Koracevic, G., additional, Djordjevic-Radojkovic, D., additional, Pavlovic, M., additional, Krstic, N., additional, Ciric-Zdravkovic, S., additional, Stojkovic, A., additional, Perisic, Z., additional, Apostolovic, S., additional, Faustino, A., additional, Seca, L., additional, Barra, S., additional, Caetano, F., additional, Providencia, R., additional, Silva, J., additional, Gomes, P., additional, Costa, G., additional, Costa, M., additional, Leitao-Marques, A., additional, Volkova, A. L., additional, Arutyunov, G. P., additional, Bylova, N. A., additional, Dayter, I. I., additional, Jao, Y. T. F. N., additional, Fang, C. C., additional, Chen, Y., additional, Yu, C. L., additional, Wang, S. P., additional, Valencia, J., additional, Perez-Berbel, P., additional, Ruiz-Nodar, J. M., additional, Pineda, J., additional, Bordes, P., additional, Quintanilla, M., additional, Mainar, V., additional, Sogorb, F., additional, Santos, N., additional, Serrao, M., additional, Cafe, H., additional, Silva, B., additional, Oliveira, R., additional, Caires, G., additional, Drumond, A., additional, Araujo, J., additional, Providencia, R. A., additional, Gomes, P. L., additional, Pais, J. R., additional, Mota, P., additional, Leitao-Marques, A. M., additional, Farhan, S., additional, Jarai, R., additional, Tentzeris, I., additional, Vogel, B., additional, Freynhofer, M. K., additional, Wojta, J., additional, Huber, K., additional, Poli, M., additional, Trambaiolo, P., additional, Corsi, F., additional, De Luca, M., additional, Mustilli, M., additional, Lukic, V., additional, Simonetti, M., additional, Ferraiuolo, G., additional, Lettino, M., additional, Casella, G., additional, Conte, M. R., additional, De Luca, L., additional, Geraci, G., additional, Ceravolo, R., additional, Pani, A., additional, Fradella, G., additional, Schratter, A., additional, Thiele, H., additional, Klemm, T., additional, Demmin, K., additional, Lehmann, D., additional, Mende, M., additional, Schuler, G., additional, Pittl, U., additional, Chernova, A., additional, Nikulina, S. U., additional, Naruke, T., additional, Inomata, T., additional, Yanagisawa, T., additional, Maekawa, E., additional, Mizutani, T., additional, Shinagawa, H., additional, Nishii, M., additional, Takeuchi, I., additional, Takehana, H., additional, Izumi, T., additional, Paulo, C., additional, Mascarenhas, J., additional, Patacho, M., additional, Pimenta, J., additional, Bettencourt, P., additional, Nardai, S., additional, Szabo, G. Y., additional, Berta, B., additional, Edes, I., additional, Merkely, B., additional, Delgado Silva, J., additional, Baptista, R., additional, Faria, R., additional, Trigo, J., additional, Gago, P., additional, Gheorghe, G., additional, Nanea, I. T., additional, Cristea, A., additional, Almarichi, S., additional, Martins, H., additional, Saraiva, F., additional, Jorge, E., additional, Mendes, P. L., additional, Monteiro, P., additional, Costa, S., additional, Franco, F., additional, Providencia, L. A., additional, Nanea, T., additional, Gheorghe, G. S., additional, Visan, S., additional, Paun, N., additional, Gaber, R., additional, Delewi, R., additional, Nijveldt, R., additional, De Bruin, H. A., additional, Hirsch, A., additional, Van Der Laan, A., additional, Bouma, B. J., additional, Tijssen, J. P. G., additional, Van Rossum, A. C., additional, Zijlstra, F., additional, Piek, J. J., additional, Rus, H., additional, Donea, M., additional, Ciurea, C., additional, Ifteni, G., additional, Casolo, G., additional, Chioccioli, M., additional, Magnacca, M., additional, Del Meglio, J., additional, Comella, A., additional, Baratto, M., additional, Lera, J., additional, Salvadori, L., additional, Tessa, C., additional, Vignali, C., additional, Keca, Z., additional, Momcilov Popin, T., additional, Panic, G., additional, White, R., additional, Mateen, F., additional, Weaver, A., additional, Agmon, Y., additional, Okisheva, E., additional, Tsaregorodtsev, D., additional, Sulimov, V., additional, Amat Santos, I. J., additional, Hernandez, C., additional, Tapia, C., additional, Campo, A., additional, Fredman, D., additional, Svensson, L., additional, Rosenqvist, M., additional, Tadel-Kocjancic, S., additional, Radsel, P., additional, Knafelj, R., additional, Gorjup, V., additional, Noc, M., additional, Zima, E., additional, Jenei, Z. S., additional, Kovacs, E., additional, Osztheimer, I., additional, Molnar, L., additional, Horvath, A., additional, Becker, D., additional, Geller, L., additional, Maggi, R., additional, Furukawa, T., additional, Viscardi, V., additional, Brignole, M., additional, Leal, S. R. N., additional, Dores, H., additional, Rosario, I., additional, Monge, J., additional, Carvalho, M. J., additional, Arroja, I., additional, Leitao, A., additional, Fonseca, C., additional, Aleixo, A., additional, Silva, A., additional, Keuleers, S., additional, Herijgers, P., additional, Herregods, M. C., additional, Budts, W., additional, Dubois, C., additional, Meuris, B., additional, Verhamme, P., additional, Flameng, W., additional, Van De Werf, F., additional, Adriaenssens, T., additional, Badran, H., additional, Elnoamany, M., additional, Lolah, T., additional, Olariu, C., additional, Macarie, C., additional, Mollik, M. A. H., additional, Hassan, A. I., additional, Paul, T. K., additional, Haque, M. Z., additional, Jahan, R., additional, Rahmatullah, M., additional, Khatun, M. A., additional, Rahman, M. T., additional, Chowdhury, M. H., additional, Bustamante Munguira, J., additional, Tamayo, E., additional, Garcia-Cuenca, I., additional, Bustamante, E., additional, Gualis, J., additional, Gomez-Martinez, M. L., additional, Florez, S., additional, Gomez-Herreras, J. I., additional, Ramirez Rodriguez, R., additional, Ramirez Rodriguez, A. M., additional, Garcia-Bello, M. A., additional, Hernadez Ortega, E., additional, Caballero Dorta, E., additional, Garcia Quintana, A., additional, Piro Mastraccio, V., additional, Medina Fernandez Aceytuno, A., additional, Assanelli, E., additional, De Metrio, M., additional, Rubino, M., additional, Lauri, G., additional, Cabiati, A., additional, Campodonico, J., additional, Grazi, M., additional, Moltrasio, M., additional, Marana, I., additional, Marenzi, G., additional, Lovlien, M., additional, Schei, B., additional, Picon-Heras, R., additional, Acebal, C., additional, Garcia Rubira, J. C., additional, Vivas Balcones, D., additional, Nunez-Gil, I., additional, Ruiz-Mateos, B., additional, Ibanez, B., additional, Fernandez-Ortiz, A., additional, Vintila, V. D., additional, Enescu, O. A., additional, Stoicescu, C. I., additional, Udroiu, C., additional, Cinteza, M., additional, Tatu - Chitoiu, G., additional, Vinereanu, D., additional, Fresco, C., additional, De Biasio, M., additional, Muser, D., additional, Sappa, R., additional, Morocutti, G., additional, Bernardi, G., additional, Proclemer, A., additional, Fontanella, B., additional, Affatato, A., additional, Ciccarese, C., additional, Sacchini, M., additional, Volpini, M., additional, Bianchetti, F., additional, Verzura, G., additional, Dei Cas, L., additional, Pudil, R., additional, Blaha, V., additional, Vojacek, J., additional, Paraskevaidis, I., additional, Ikonomidis, I., additional, Parissis, J., additional, Papadopoulos, C., additional, Stasinos, V., additional, Bistola, V., additional, Anastasiou-Nana, M., additional, Shochat, M., additional, Shotan, A., additional, Kazatsker, M., additional, Gurovich, V., additional, Asif, A., additional, Noiman, E., additional, Levy, Y., additional, Blondhaim, D., additional, Rabinovich, P., additional, Meisel, S., additional, Petrovic, S., additional, Glasnovic, J., additional, Tomasevic, M., additional, Sakac, D., additional, Obradovic, S., additional, Londono Sanchez, O., additional, Pacreu, S., additional, Torres, L., additional, Mihaylov, G., additional, Shaban, G. M., additional, Trendafilova, E., additional, Krasteva, V., additional, Mudrov, T. S., additional, Didon, J. P., additional, Panageas, V., additional, Vlachos, N., additional, Pernat, A., additional, Radan, I., additional, Mozina, H., additional, Pepi, P., additional, Cionini, F., additional, Baccaglioni, N., additional, Viertel, A., additional, Havers, J., additional, Ballard, G., additional, Groenefeld, G., additional, Branco, L. M., additional, Ferreira, L., additional, Fiarresga, A., additional, Lettieri, L., additional, Reggiani, A., additional, Juarez Prera, R., additional, Blanco Palacios, G., additional, Martin, A.- C., additional, Manzo Silberman, S., additional, Chaib, A., additional, Varenne, O., additional, Allouch, P., additional, Salengro, E., additional, Jegou, A., additional, Margot, O., additional, Spaulding, C., additional, Diego, A., additional, De Miguel, A., additional, Cuellas, C., additional, Fraile, E., additional, Martin, J., additional, Vega, B., additional, Bangueses, R., additional, Fernandez-Vazquez, F., additional, Perez De Prado, A., additional, Leal, S., additional, Correia, M. J., additional, Monge, J. C., additional, Abecasis, J., additional, Garcia-Garcia, C., additional, Subirana, I., additional, Sala, J., additional, Bruguera, J., additional, Valle, V., additional, Sanz, G., additional, Fiol, M., additional, Aros, F., additional, Marrugat, J., additional, Elosua, R., additional, Barra, S. N. C., additional, Leitao Marques, A., additional, Yang, Y. J., additional, Xu, B., additional, Song, G. Y., additional, G, R. L., additional, Aleksic, A., additional, Serpytis, P., additional, Rucinskas, K., additional, Kalinauskas, A., additional, Karvelyte, N., additional, Santos De Sousa, C. I., additional, Ferreira, S., additional, Calaca, J., additional, Lousada, N., additional, Palma Reis, R., additional, Gualandro, D. M., additional, Seguro, L. F. B. C., additional, Braga, F. G. M., additional, Silvestre, O. M., additional, Lage, R. L., additional, Fabri, J., additional, Oliveira, M. T., additional, Urbano Moral, J. A., additional, Torres Llergo, J., additional, Solanilla Rodriguez, R., additional, Sanchez Gonzalez, A., additional, Martinez Martinez, A., additional, Den Uil, C. A., additional, Lagrand, W. K., additional, Van Der Ent, M., additional, Jewbali, L. S. D., additional, Cheng, J. M., additional, Spronk, P. E., additional, Simoons, M. L., additional, Mornos, C., additional, Dragulescu, D., additional, Ionac, A., additional, Guardado, J., additional, Azevedo, O., additional, Fernandes, M., additional, Canario-Almeida, F., additional, Sanfins, V., additional, Pereira, A., additional, Almeida, J., additional, Kaplunova, V. U., additional, Belenkov, Y. N., additional, Privalova, E. V., additional, Fomin, A. A., additional, Suvorov, A. Y., additional, Goodkova, A., additional, Rubakova, M. G., additional, Kuznetsova, I. A., additional, Semernin, E. N., additional, Keshavarzi, F., additional, Kojuri, J., additional, Mikhailov, V. M., additional, Vezhenkova, I. V., additional, Goodkova, A. Y. A., additional, Pavlovic, I., additional, Schwarz, M., additional, Jakl, G., additional, Smetana, P., additional, Perkmann, T., additional, Mayr, A., additional, Mair, J., additional, Klug, G., additional, Schocke, M., additional, Trieb, T., additional, Jaschke, W., additional, Pachinger, O., additional, Metzler, B., additional, Bronze Carvalho, L., additional, Azevedo, J., additional, Andrade, M. L., additional, Relvas, M. J., additional, Coucello, J., additional, Morais, G., additional, Seabra, M., additional, Afamefule, F., additional, Luaces Mendez, M., additional, Teijeiro-Mestre, R., additional, Nunez-Gil, I. J., additional, Leco-Gil, N., additional, Madronal-Cerezo, E., additional, Zannin, I., additional, Ruiz, J., additional, Orynchak, M. A., additional, Vakalyuk, I. I., additional, Vakalyuk, I. P., additional, Berezin, A., additional, Panasenko, T., additional, Cavusoglu, Y., additional, Cavusoglu, A., additional, Unluoglu, I., additional, Tek, M., additional, Demirustu, C., additional, Gorenek, B., additional, Unalacak, M., additional, Birdane, A., additional, Yuksel, F., additional, Ata, N., additional, Halcox, J. P. J., additional, Beyaztas, A., additional, Entok, E., additional, Uslu, I., additional, Schaefer, A., additional, Flierl, U., additional, Seydelmann, N., additional, Bauersachs, J., additional, Calmac, L., additional, Marinescu, S., additional, Tatu Chitoiu, G., additional, Fruntelata, A. G., additional, Hamdi, S., additional, Maazoun, Y., additional, Neji, A., additional, Farhat, O., additional, Majdoub, M., additional, Ben Hamda, K., additional, Maatouk, F., additional, Balanescu, S. M., additional, Nedelciuc, I., additional, Deleanu, D., additional, Ortan, F., additional, Mot, S., additional, Sinnaeve, P. R., additional, Moreels, S., additional, Coosemans, M., additional, Vydt, T., additional, Desmet, W., additional, Tobing, D., additional, Rifnaldi, R., additional, Juzar, D., additional, Firdaus, I., additional, Dharma, S., additional, Irmalita, I., additional, Kalim, H., additional, Bejiqi, R., additional, Retkoceri, R., additional, Bejiqi, H., additional, Kryeziu, L., additional, Kelmendi, M., additional, Borovci, S. H., additional, Victor, S. M., additional, Gnanaraj, A., additional, Deshmukh, R., additional, Mullasari, A. S., additional, Yahalom, M., additional, Kaiyal, R. S., additional, Roguin, N., additional, Bornstein, J., additional, Atar, S., additional, Farah, R., additional, Seca, L. F., additional, Leitao Marques, A. M., additional, Margato, R., additional, Sousa, P., additional, Ribeiro, H., additional, Rocha, L., additional, Correia, A., additional, Moreira, J. I., additional, Carvalho, H. C., additional, Afifi, M., additional, Abed, N., additional, Suarez-Barrientos, A., additional, Vivas, D., additional, Castro-Ferreira, F., additional, Franco, E., additional, Garcia-Rubira, J. C., additional, Fuster, V., additional, Macaya, C., additional, Ibanez Cabeza, B., additional, Salinger, S., additional, Milic, D., additional, Stanojlovic, T., additional, Kostic, T., additional, Khan, M. A., additional, Vrapi, F., additional, Naeem, K., additional, Davar, J., additional, Hristova, K., additional, Pencheva, G., additional, Radeva, R., additional, Milanov, S., additional, Fareed, A., additional, Oraby, M., additional, Nasr, G. M., additional, Maklady, F., additional, Dupouy, P., additional, Sorensen, J. T., additional, Terkelsen, C. J., additional, Lassen, J. F., additional, Trautner, S., additional, Christensen, E. F., additional, Nielsen, T. T., additional, Botker, H. E., additional, Andersen, H. R., additional, Thygesen, K. A., additional, Checco, L., additional, Usmiani, T., additional, Sbarra, P. L., additional, Boffini, M., additional, Saviolo, R., additional, Grasso, C., additional, Conrotto, F., additional, Marchetti, M., additional, Rinaldi, M., additional, Marra, S., additional, Moscoso Costa, F., additional, Ferreira, J., additional, Raposo, L., additional, Aguiar, C., additional, Trabulo, M., additional, Silva, J. A., additional, Marques, V., additional, Swiatkowski, A., additional, Kowalczyk, J., additional, Lenarczyk, R., additional, Chodor, P., additional, Honisz, G., additional, Was, T., additional, Swierad, M., additional, Sredniawa, B., additional, Polonski, L., additional, Kalarus, Z., additional, Postadzhiyan, A. S., additional, Velinov, H., additional, Velchev, V., additional, Hazarbasanov, D., additional, Apostolova, M., additional, Finkov, B., additional, Petrovic, M., additional, Jovelic, A., additional, Canji, T., additional, Srdanovic, I., additional, Popov, T., additional, Golubovic, M., additional, Pavlovic, K., additional, Cemerlic-Adjic, N., additional, Bro-Jeppesen, J., additional, Kjaergaard, J., additional, Wanscher, M. C., additional, Nielsen, S. L., additional, Rasmussen, L. S., additional, Hassager, C., additional, Khan, M., additional, Crolla, E., additional, Morley, H., additional, Akeroyd, L., additional, Beaini, Y., additional, Morley, C., additional, Bekeredjian, R. H., additional, Krumsdorf, U., additional, Rottbauer, W., additional, Katus, H. A., additional, Pleger, S., additional, Botelho, A., additional, Quintal, N., additional, Faria, P., additional, Gomes, S., additional, Roussel, J. C., additional, Senage, T., additional, Perigaud, C., additional, Habash, O., additional, Michel, M., additional, Treilhaud, M., additional, Despins, P., additional, Trochu, J. N., additional, Baron, O., additional, Duveau, D., additional, Kitsiou, A. N., additional, Giannakopoulos, K., additional, Papadimitriou, G., additional, Karas, S., additional, Babic, Z., additional, Nikolic Heitzler, V., additional, Milicic, D., additional, Bergovec, M., additional, Raguz, M., additional, Mirat, J., additional, Strozzi, M., additional, Plazonic, Z., additional, Giunio, L., additional, Steiner, R., additional, Freynhofer, M., additional, Brozovic, I., additional, Bruno, V., additional, Leherbauer, L., additional, Djurkovic, M., additional, Willheim, M., additional, Huebl, W., additional, Hahne, S., additional, Kozanli, I., additional, Kalla, K., additional, Geppert, A., additional, Unger, G., additional, Simoes Marques Assuncao Caetano, A. F., additional, Faustino, C., additional, Ariza Sole, A., additional, Sanchez Salado, J. C., additional, Lorente Tordera, V., additional, Martinez Garcia, V., additional, Salazar Mendiguchia Y Garcia, J., additional, Gomez Hospital, J. A., additional, Maristany Daunert, J., additional, Berdejo Gago, F. J., additional, Esplugas Oliveras, E., additional, Brzozowska-Czarnek, A., additional, Urbanik, A., additional, Kakouros, N., additional, Kakouros, S., additional, Lekakis, J., additional, Rizos, J., additional, Kokkinos, D., additional, Venevtseva, J., additional, Melnikov, A., additional, Valiahmetov, M., additional, Gomova, T., additional, Perelomova, I., additional, Ferrer Hita, J. J., additional, Bosa-Ojeda, F., additional, Sanchez-Grande-Flecha, A., additional, Yanes-Bowden, G., additional, Vargas-Torres, M. J., additional, Rodriguez-Gonzalez, A., additional, Rubio-Iglesias-Garcia, C., additional, Dominguez-Rodriguez, A., additional, Enjuanes-Grau, C., additional, Marrero-Rodriguez, F., additional, Suceveanu, A. I., additional, Suceveanu, A., additional, Mazilu, L., additional, Alexandrescu, L., additional, Dumitru, E., additional, Miu, V., additional, Jitari, V., additional, Voinea, F. L., additional, Balachandran, K. P., additional, Schofield, R., additional, Sankaranarayanan, R., additional, Helm, K., additional, Crowe, C., additional, Singh, R., additional, Mcdonald, J., additional, Chuen, M. J., additional, Kobusiak-Prokopowicz, M., additional, Preglowska, M., additional, Mysiak, A., additional, Doi, T., additional, Sakoda, T., additional, Akagami, T., additional, Naka, T., additional, Tsujino, T., additional, Masuyama, T., additional, Ohyanagi, M., additional, Kume, N., additional, Mitsuoka, H., additional, Hayashida, K., additional, Tanaka, M., additional, Biasucci, L. M., additional, Della Bona, R., additional, Biasillo, G., additional, Leo, M., additional, Zaninotto, M., additional, Plebani, M., additional, Crea, F., additional, Dellabona, R., additional, Gok, B., additional, Unalir, A., additional, Timuralp, B., additional, Nikulina, N., additional, Yakushin, S. S., additional, Furmenko, G. I., additional, Akinina, S. A., additional, Ingrid, R., additional, Bronze, L., additional, Djambazov, S., additional, Zhivkov, A., additional, Maznev, I., additional, Ingeliev, M., additional, Slavov, R., additional, Cvetkova, N., additional, Patarinski, V., additional, Groch, L., additional, Horak, J., additional, Dimitrov, N., additional, Hayrapetyan, H. G., additional, Cabanas-Grandio, P., additional, Pena-Gil, C., additional, Mc Keag, N. A., additional, Mc Cann, C. J., additional, Cardwell, C., additional, Young, I. S., additional, Mikhalchikova, N., additional, Burova, N., additional, Zaccaria, M., additional, Palmisano, P., additional, Palumbo, V., additional, Ciccone, M. M., additional, Favale, S., additional, Chen, K. C., additional, Yin, W. H., additional, Liu, J. H., additional, Goncalves, S., additional, Santos, J. F., additional, Amador, P., additional, Soares, L. N., additional, Zahidova, K., additional, Guliyev, F., additional, Zahidov, N., additional, Carrilho-Ferreira, P., additional, Marques, J. S., additional, Carvalho De Sousa, J., additional, Uthoff, H., additional, Thalhammer, C., additional, Potocki, M., additional, Reichlin, T., additional, Noveanu, M., additional, Aschwanden, M., additional, Staub, D., additional, Arenja, N., additional, Socrates, T., additional, Mueller, C., additional, Zhao, Y., additional, Wu, X., additional, Xue, Q., additional, Gao, L., additional, Lin, H., additional, Wang, S., additional, Watanabe, K., additional, Kawamura, A., additional, Seko, T., additional, Omura, A., additional, Sakabe, S., additional, Kasai, A., additional, Starodubova, A. V., additional, Storozhakov, G., additional, Kisliak, O., additional, Hautieva, F., additional, Tursheva, M., additional, Fedotova, N., additional, Di Maio, R. C., additional, Mclaughlin, J., additional, Allen, J. D., additional, Anderson, J. M. C., additional, Khaled Nagi, H., additional, Tayeh, O., additional, Farok, W., additional, Mousa, A., additional, Neuzil, P., additional, Skoda, J., additional, Petru, J., additional, Sediva, L., additional, Kralovec, S., additional, Holy, F., additional, Holdova, K., additional, Jehlicka, P., additional, Plasil, P., additional, Reddy, V. Y., additional, Alabakovska, S., additional, Labudovic, D., additional, Jovanova, S., additional, Tosheska, K., additional, Alabakovski, M., additional, Jeevaratnam, K., additional, Tee, S. P., additional, Zhang, Y., additional, Guzadhur, L., additional, Gurung, I. S., additional, Duehmke, R., additional, Grace, A. A., additional, Lei, M., additional, Huang, C. L., additional, Ishibashi, Y., additional, Yamauchi, M., additional, Akashi, Y., additional, Musha, H., additional, Miyake, F., additional, Hnatek, T., additional, Kamenik, L., additional, Sedlon, P., additional, Luxova, J., additional, Steuerova, B., additional, Skvaril, J., additional, Cernohous, M., additional, Zavoral, M., additional, Ratkovic, N., additional, Nemanja Djenic, N. R., additional, Aleksandra Jovelic, A. J., additional, Slobodan Obradovic, S. O., additional, Branko Gligic, B. G., additional, Kletsiou, E., additional, Giannakopoulou, M., additional, Bozas, E., additional, Iliodromitis, E. K., additional, Papathanassoglou, E. D. E., additional, Anton, M., additional, Anton, G., additional, Muraru, M., additional, Salinger Martinovic, S., additional, Radosavljevic, M., additional, Stanojevic, D., additional, Zivkovic, M., additional, Pessoa, T., additional, Aspromonte, N., additional, Ronco, C., additional, Tubaro, M., additional, Santini, M., additional, Colivicchi, F., additional, Aiello, A., additional, Cruz, D., additional, Anzoletti Boscolo, A., additional, Vianello, G., additional, Valle, R., additional, Parspour, A., additional, Watkins, S., additional, Datta, D., additional, Nikishin, A. G., additional, Pirnazarov, M. M., additional, Nurbaev, T. A., additional, Motovska, Z., additional, Fischerova, M., additional, Osmancik, P., additional, Maly, M., additional, Widimsky, P., additional, Pavli, E., additional, Dibra, A., additional, Mehilli, J., additional, Dibra, L., additional, Schoemig, A., additional, Kastrati, A., additional, Carmo, P., additional, Almeida, M., additional, Teles, R., additional, Goncalves, P., additional, Brito, J., additional, D'ascenzo, F., additional, Gonella, A., additional, Longo, G., additional, Pullara, A., additional, Moretti, C., additional, Sciuto, F., additional, Omede', P., additional, Biondi Zoccai, G., additional, Trevi, G. P., additional, Sheiban, I., additional, Cafe, H. M., additional, Pereira, D., additional, Freitas, D., additional, Ortiz Berbel, D., additional, Rabasa Baraibar, J. M., additional, Leone, A. M., additional, De Caterina, A., additional, Aurelio, A., additional, Sciahbasi, A., additional, Lioy, E., additional, Trani, C., additional, Burzotta, F., additional, Porto, I., additional, Rebuzzi, A. G., additional, Trusinskis, K., additional, Juhnevica, D., additional, Strenge, K., additional, Sondore, D., additional, Kumsars, I., additional, Jegere, S., additional, Narbute, I., additional, Grave, A., additional, Zakke, I., additional, Erglis, A., additional, Ferrari, C., additional, Bartorelli, A. L., additional, Saeed, M., additional, Cozma, D., additional, Pescariu, S., additional, Dragulescu, S. I., additional, Kamal, H. S., additional, Abdelfattah, A., additional, Abdelbary, A. M., additional, Elassar, H., additional, Naggar, A., additional, Khaled, M., additional, Fareed, A. M., additional, Pernes, J. M., additional, Gaux, J. C., additional, Prull, M. W., additional, Sasko, B., additional, Wirdemann, H., additional, Bittlinsky, A., additional, Butz, T., additional, Trappe, H. J., additional, Perazzolo Marra, M., additional, Cacciavillani, L., additional, Marzari, A., additional, De Lazzari, M., additional, Turri, R., additional, China, P., additional, Corbetti, F., additional, Iliceto, S., additional, Stazhadze, L. L., additional, Spiridonova, E. A., additional, Bulanova, N. A., additional, Ermolaev, A. A., additional, Savic, L., additional, Mrdovic, I., additional, Krljanac, G., additional, Perunicic, J., additional, Asanin, M., additional, Lasica, R., additional, Matic, M., additional, Vasiljevic, Z., additional, Ostojic, M., additional, Tichy, M., additional, Andrys, C., additional, Conti, A., additional, Poggioni, C., additional, Viviani, G., additional, Bulletti, F., additional, Boni, V., additional, Luzzi, M., additional, Vicidomini, S., additional, Donati, M., additional, Del Taglia, B., additional, Pini, R., additional, Sousa, O., additional, Fontes-Carvalho, R., additional, Caeiro, D., additional, Dias Ferreira, N., additional, Silva, G., additional, Pereira, E., additional, Ribeiro, J., additional, Albuquerque, A., additional, Gama Ribeiro, V., additional, Murai, M., additional, Takeda, Y., additional, Shinmyo, T., additional, Tanigawa, J., additional, Hazui, H., additional, Nakakohji, T., additional, Ohishi, Y., additional, Hoshiga, M., additional, Ishihara, T., additional, Hanafusa, T., additional, Belohlavek, J., additional, Rohn, V., additional, Kunstyr, J., additional, Lips, M., additional, Semrad, M., additional, Mlejnsky, F., additional, Tosovsky, J., additional, Linhart, A., additional, Lindner, J., additional, Sablik, Z., additional, Samborska-Sablik, A., additional, Drozdz, J., additional, Gaszynski, W., additional, Izquierdo-Gomez, M. M., additional, Juarez-Prera, R., additional, Blanco-Palacios, G., additional, Lakhdar, R., additional, Drissa, M., additional, Jedaida, B., additional, Drissa, H., additional, Sampaio, F., additional, Hsin, H.- T., additional, Huang, J.- H., additional, Chiu, K.- M., additional, Chen, Z.- S., additional, Lin, P.- C., additional, Chen, L.- Y., additional, Chu, S.- H., additional, Efthimiadis, I., additional, Skendros, P., additional, Sarantopoulos, A., additional, Boura, P., additional, Van Der Laan, A. M., additional, Van Der Vleuten, P. A., additional, Klees, M., additional, Tijssen, J. G. P., additional, Backus, B. E., additional, Six, A. J., additional, Kelder, J. H., additional, Mosterd, A., additional, Mast, E. G., additional, Mast, T. P., additional, Braam, R., additional, Tio, R., additional, Veldkamp, R., additional, Doevendans, P. A., additional, Paarup Dridi, N., additional, Holmvang, L., additional, Engstroem, T., additional, Rekik, S., additional, Brunet, J., additional, Hager, F. X., additional, Bayet, G., additional, Meille, L., additional, Quatre, J. M., additional, Sainsous, J., additional, Chu, P.- H., additional, Tang, C.- H., additional, Pogosova, N., additional, Koltunov, I. E., additional, Sapunova, I. D., additional, Vigodin, V. A., additional, Uhliar, R., additional, Schmidt, A., additional, Brockmeyer, B., additional, Suzuki, A., additional, Eki, Y., additional, Higuchi, H., additional, Yukawa, A., additional, Yamauchi, R., additional, Sato, Y., additional, Endo, Y., additional, Salazar Mendigucha Garcia, J., additional, Homs Vila, S., additional, Cequier Fillat, A., additional, Andion Ogando, R., additional, Sandin Fuentes, M., additional, Vegas Valle, J. M., additional, Gonzalez Garcia, I. A., additional, Duro Aguado, I. A., additional, Palomino Doza, A. J., additional, Gomez Salvador, I., additional, San Roman Calvar, J. A., additional, Mamarasulov, T. M., additional, Todorovic, L., additional, Cherneva, Z. C. H., additional, Denchev, S. D., additional, Heltai, K., additional, Boytsov, A., additional, Nikulina, N. N., additional, Zanna, D., additional, Marangelli, V., additional, Caiati, C., additional, Picon Heras, R., additional, Loureiro, M. J., additional, Urazovskaya, I., additional, Vinogradova, D., additional, Vasilieva, E., additional, Shpektor, A., additional, Conti, E., additional, Musumeci, M. B., additional, Lauri, F. M., additional, Dito, E., additional, De Giusti, M., additional, Lallo, A., additional, Fusco, D., additional, Davoli, M., additional, Volpe, M., additional, Autore, C., additional, Gamra, H., additional, Dridi, Z., additional, Hassine, M., additional, Addad, F., additional, Gherissi, I., additional, Reda, A., additional, Mahjoub, M., additional, Bouraoui, S., additional, Abdennadher, M., additional, Betbout, F., additional, Mota, P. M. F. P., additional, Silva, J. D., additional, Jankovic Tomasevic, R., additional, Djordjevic, V., additional, Djordjevic Radojkovic, D., additional, Scafa Udriste, A., additional, Fruntelata, A., additional, Gainoiu, E., additional, Bogdan, S., additional, Zamfir, D., additional, Teodorescu, C., additional, Guran, M., additional, Constantinescu, D., additional, Konopka, A., additional, Banaszewski, M., additional, Wojtkowska, I., additional, Stepinska, J., additional, Vidergold, J. V., additional, Osipova, I. V., additional, Tavrovskaya, T. V., additional, Galkina, J. V., additional, Timofeev, A. V., additional, Vorobyov, R. I., additional, Vorobyova, E. N., additional, Matos, L., additional, Carvalho, A. C. C., additional, Oliveira, W., additional, Cintra, F., additional, Poyares, D., additional, Andersen, M., additional, Martins, R., additional, Tufik, S., additional, Ostadal, P., additional, Brada, J., additional, Horakova, S., additional, Mlcek, M., additional, Hrachovina, V., additional, Kittnar, O., additional, Gorudko, I. V., additional, Buko, I. V., additional, Cherenkevich, S. N., additional, Polonetsky, L. Z., additional, Plotkin, V. Y., additional, Timoshina, M. A., additional, Azanchevskaya, S. V., additional, Chromov-Borisov, N. N., additional, Vorlat, A., additional, Snoep, L., additional, Claeys, M. J., additional, Vrints, C. J., additional, Palazzuoli, A., additional, Caputo, M., additional, Quatrini, I., additional, Calabro, A., additional, Antonelli, G., additional, Campagna, M. S., additional, Franci, B., additional, Nuti, R., additional, Maisel, A., additional, Negrini, M., additional, Minora, T., additional, Marino, P., additional, Seregni, R., additional, Tavlueva, E., additional, Barbarash, O., additional, Barbarash, L., additional, Janota, T., additional, Kudlicka, J., additional, Malik, K., additional, Wichterle, D., additional, Hradec, J., additional, Body, R., additional, Carley, S. D., additional, Mcdowell, G., additional, Nuttall, M., additional, Wibberley, C., additional, France, M., additional, Cruickshank, J. K., additional, Mackway-Jones, K., additional, Leon, M., additional, Cozma, C., additional, Mitu, F., additional, Almeida, D. R., additional, Dias, C. B., additional, Burazor, I., additional, Burazor, M., additional, Krstic, M., additional, Lazovic, M., additional, Vukmanovic, M., additional, Djordjevic, J., additional, Radovanovic, Z., additional, Ilic, D., additional, Bosnjakovic, P., additional, Ferreira, A. C., additional, Mateus, P. S., additional, Fontes, P., additional, Teixeira, T., additional, Conte, G., additional, Menozzi, A., additional, Solinas, E., additional, Bolognesi, M. G., additional, Tadonio, I., additional, Mantovani, F., additional, Cattabiani, A., additional, Vignali, L., additional, Ardissino, D., additional, Tautu, O., additional, Alexandrescu, A., additional, Niculescu, R., additional, Jankovic, R., additional, Bozinovic, N., additional, Santos, C., additional, Costa, F., additional, Cardoso, G., additional, Correia, I., additional, Fountoulaki, K., additional, Kastellanos, S., additional, Voltirakis, E., additional, Kokotos, A., additional, Michalakeas, C., additional, Kontsas, K., additional, Hasioti, K., additional, Iliodromitis, E. T., additional, Sandin Fuentes, M. G., additional, Zatarain Nicolas, E., additional, Martinez Uruena, N., additional, Alvarado Montes De Oca, M., additional, Dytrych, V., additional, Kovarnik, T., additional, Smid, O., additional, Kral, A., additional, Aroutunov, A. G., additional, Intwala, S., additional, Jegere, I., additional, Shaalan, H. S. H., additional, Pagava, Z., additional, Agladze, R., additional, Shakarishvili, R., additional, Sharashidze, N., additional, Gujejiani, L., additional, Saatashvili, G., additional, Katova, T. Z., additional, Kostova, V., additional, Simova, Y., additional, Vukotic, S., additional, Rafajlovski, S., additional, Romanovic, R., additional, Antonijevic, N., additional, Gligic, B., additional, Hutyra, M., additional, Skala, T., additional, Horak, D., additional, Vindis, D., additional, Taborsky, M., additional, Contine, A., additional, Del Pinto, M., additional, Angeli, F., additional, Verdecchia, P., additional, Borgognoni, F., additional, Grikstaite, E., additional, Pantano, P., additional, Ambrosio, G., additional, Cavallini, C., additional, Bonanad, C., additional, Sanchis, J., additional, Bodi, V., additional, Nunez, J., additional, Bosch, X., additional, Heras, M., additional, Pellicer, M., additional, Llacer, A., additional, Adao, L., additional, Oliveira, M., additional, Goncalves, H., additional, Primo, J., additional, Gama, V., additional, Lombardi, C., additional, Metra, M., additional, Bugatti, S., additional, Pasotti, E., additional, Quinzani, F., additional, Adamo, M., additional, Villa, C., additional, Rovetta, R., additional, Manerba, A., additional, Mariani, M., additional, Dushpanova, A., additional, Baroni, M., additional, Cerone, E., additional, Nardelli, A., additional, Gianetti, J., additional, Berti, S., additional, Feliciano, F., additional, Soares, R., additional, Santos, S., additional, Kruger, A., additional, Vondrakova, D., additional, Herget, J., additional, Navarro, C., additional, Cromie, N. A., additional, Adgey, J. A. A., additional, Caeiro Pereira, D., additional, Braga, P., additional, Fontes Carvalho, R., additional, Rodrigues, A., additional, Goncalves, M., additional, Simoes, L., additional, and Borisov, K. V., additional
Published: 2010
Full Text: View/download PDF

34. Transradial Crossover Balloon Occlusion Technique for Primary Access Hemostasis During Transcatheter Aortic Valve Replacement: Initial Experience With the Oceanus 140 cm and 200 cm Balloon Catheters

Author: Junquera L, Vilalta V, RAMIRO TRILLO, Sabaté M, Latib A, Nombela-Franco L, Moris C, Garcia Del Blanco B, Larman M, Jm, Hernandez, Iñiguez A, Amat-Santos I, and Rodés Cabau J

35. Complete or Culprit-Only PCI in Older Patients with Myocardial Infarction.

Author: Biscaglia, S., Guiducci, V., Escaned, J., Moreno, R., Lanzilotti, V., Santarelli, A., Cerrato, E., Sacchetta, G., Jurado-Roman, A., Menozzi, A., Amat Santos, I., Díez Gil, J. L., Ruozzi, M., Barbierato, M., Fileti, L., Picchi, A., Lodolini, V., Biondi-Zoccai, G., Maietti, E., and Pavasini, R.
Subjects: *MYOCARDIAL infarction, *OLDER patients, *ST elevation myocardial infarction, *PERCUTANEOUS coronary intervention, *ACUTE kidney failure
Abstract: BACKGROUND The benefit of complete revascularization in older patients (≥ 75 years of age) with myocardial infarction and multivessel disease remains unclear. METHODS In this multicenter, randomized trial, we assigned older patients with myocardial infarction and multivessel disease who were undergoing percutaneous coronary intervention (PCI) of the culprit lesion to receive either physiology-guided complete revascularization of nonculprit lesions or to receive no further revascularization. Functionally significant nonculprit lesions were identified either by pressure wire or angiography. The primary outcome was a composite of death, myocardial infarction, stroke, or any revascularization at 1 year. The key secondary outcome was a composite of cardiovascular death or myocardial infarction. Safety was assessed as a composite of contrast-associated acute kidney injury, stroke, or bleeding. RESULTS A total of 1445 patients underwent randomization (720 to receive complete revascularization and 725 to receive culprit-only revascularization). The median age of the patients was 80 years (interquartile range, 77 to 84); 528 patients (36.5%) were women, and 509 (35.2%) were admitted for ST-segment elevation myocardial infarction. A primary-outcome event occurred in 113 patients (15.7%) in the complete-revascularization group and in 152 patients (21.0%) in the culprit-only group (hazard ratio, 0.73; 95% confidence interval [CI], 0.57 to 0.93; P = 0.01). Cardiovascular death or myocardial infarction occurred in 64 patients (8.9%) in the complete-revascularization group and in 98 patients (13.5%) in the culprit-only group (hazard ratio, 0.64; 95% CI, 0.47 to 0.88). The safety outcome did not appear to differ between the groups (22.5% vs. 20.4%; P=0.37). CONCLUSIONS Among patients who were 75 years of age or older with myocardial infarction and multivessel disease, those who underwent physiology-guided complete revascularization had a lower risk of a composite of death, myocardial infarction, stroke, or ischemia-driven revascularization at 1 year than those who received culprit-lesion-only PCI. [ABSTRACT FROM AUTHOR]
Published: 2023
Full Text: View/download PDF

36. Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial

Author: Francesco Giannini, Andrea Santarelli, Ferdinando Varbella, Iginio Colaiori, Raul Moreno, Enrique Gutiérrez Ibañes, Mila Menozzi, José Luis Díez Gil, Marco Ruozzi, Alfredo Redondo, Javier Escaned, Valerio Lanzilotti, Antonio Colombo, Matteo Tebaldi, Elisa Maietti, Emanuele Barbato, Simone Biscaglia, Francisco Fernández-Avilés, Dariusz Dudek, Ignacio Amat Santos, Gianluca Campo, Giuseppe Biondi Zoccai, Luca Fileti, Vincenzo Guiducci, Biscaglia, S., Guiducci, V., Santarelli, A., Amat Santos, I., Fernandez-Aviles, F., Lanzilotti, V., Varbella, F., Fileti, L., Moreno, R., Giannini, F., Colaiori, I., Menozzi, M., Redondo, A., Ruozzi, M., Gutierrez Ibanes, E., Diez Gil, J. L., Maietti, E., Biondi Zoccai, G., Escaned, J., Tebaldi, M., Barbato, E., Dudek, D., Colombo, A., and Campo, G.
Subjects: Male, medicine.medical_specialty, Prognosi, medicine.medical_treatment, 030204 cardiovascular system & hematology, Revascularization, Coronary Angiography, Conservative Treatment, Severity of Illness Index, Article, NO, 03 medical and health sciences, 0302 clinical medicine, Postoperative Complications, Quality of life, Internal medicine, Functional Statu, Clinical endpoint, medicine, Myocardial Revascularization, Humans, Multicenter Studies as Topic, 030212 general & internal medicine, Myocardial infarction, Mortality, Non-ST Elevated Myocardial Infarction, Stroke, Randomized Controlled Trials as Topic, Aged, business.industry, Cardiovascular Agents, medicine.disease, Prognosis, Aged, Coronary Angiography, Cardiovascular Agents, Conservative Treatment, Functional Status, Mortality, Prognosis, Severity of Illness Index, Myocardial Revascularization, Non-ST Elevated Myocardial Infarction, Postoperative Complications, ST Elevation Myocardial Infarction, Functional Status, Cardiovascular Agent, Sample size determination, cardiovascular system, Cardiology, ST Elevation Myocardial Infarction, Female, Postoperative Complication, Cardiology and Cardiovascular Medicine, business, Medical therapy, All cause mortality, Human
Abstract: Background Myocardial infarction (MI) in elderly patients is associated with unfavorable prognosis, and it is becoming an increasingly prevalent condition. The prognosis of elderly patients is equally impaired in ST-segment elevation (STE) or non-STE (NSTE), and it is markedly worsened by the common presence of multivessel disease (MVD). Given the limited evidence available for elderly patients, it has not yet been established whether, as for younger patients, a complete revascularization strategy in MI patients with MVD should be advocated. We present the design of a dedicated study that will address this research gap. Methods and design The FIRE trial is a prospective, randomized, international, multicenter, open-label study with blinded adjudicated evaluation of outcomes. Patients aged 75years and older, with MI (either STE or NSTE), MVD at coronary artery angiography and a clear culprit lesion will be randomized to culprit-only treatment or to physiology-guided complete revascularization. The primary endpoint will be the patient-oriented composite endpoint (POCE) of all cause death, any MI, any stroke, any revascularization at one year. The key secondary endpoint will be the composite of cardiovascular death and MI. Quality of life and physical performance will be evaluated as well. All components of the primary and key secondary outcome will be tested also at 3 and 5years. The sample size for the study is 1400 patients. Implications The FIRE trial will provide evidence on whether a specific revascularization strategy should be applied to elderly patients presenting MI and MVD in order to improve their clinical outcomes.
Published: 2020

37. Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction With or Without ST-Segment Elevation.

Author: Cocco M, Campo G, Guiducci V, Casella G, Cavazza C, Cerrato E, Sacchetta G, Moreno R, Menozzi A, Amat Santos I, Díez Gil JL, Scarsini R, Picchi A, Vadalà G, Pilato G, Colaiori I, Barbierato M, Arioti M, Pavasini R, Lanzilotti V, Menozzi M, Varbella F, Erriquez A, and Biscaglia S
Subjects: Humans, Female, Male, Aged, Percutaneous Coronary Intervention methods, Aged, 80 and over, Treatment Outcome, ST Elevation Myocardial Infarction surgery, ST Elevation Myocardial Infarction mortality, ST Elevation Myocardial Infarction physiopathology, Non-ST Elevated Myocardial Infarction surgery, Non-ST Elevated Myocardial Infarction mortality, Non-ST Elevated Myocardial Infarction physiopathology, Myocardial Revascularization methods
Abstract: Background: The effectiveness of complete revascularization is well established in patients with ST-segment elevation myocardial infarction (STEMI), but it is less investigated in those with non-ST-segment elevation myocardial infarction (NSTEMI)., Objectives: This study aimed to assess whether complete revascularization, compared with culprit-only revascularization, was associated with consistent outcomes in older patients with STEMI and NSTEMI., Methods: In the FIRE (Functional Assessment in Elderly MI Patients with Multivessel Disease) trial, 1,445 older patients with myocardial infarction (MI) were randomized to culprit-only or physiology-guided complete revascularization, stratified by STEMI (n = 256 culprit-only vs n = 253 complete) and NSTEMI (n = 469 culprit-only vs n = 467 complete). The primary outcome comprised a composite of death, MI, stroke, or revascularization at 1 year. The key secondary outcome included a composite of cardiovascular death or MI at 1 year., Results: In the overall study population, physiology-guided complete revascularization reduced both primary and key secondary outcomes. The primary outcome occurred in 54 (21.1%) STEMI patients randomized to culprit-only vs 41 (16.2%) STEMI patients of the complete group (HR: 0.75; 95% CI: 0.50-1.13) and in 98 (20.9%) NSTEMI patients randomized to culprit-only vs 72 (15.4%) NSTEMI patients of the complete group (HR: 0.71; 95% CI: 0.53-0.97), with negative interaction testing (P for interaction, 0.846). Similarly, no signal of heterogeneity with respect to the initial clinical presentation was observed for the key secondary endpoint (P for interaction, 0.654)., Conclusions: Physiology-guided complete revascularization, compared with culprit-only revascularization, provided consistent benefit across the whole spectrum of patients with MI. (FIRE [Functional Assessment in Elderly MI Patients With Multivessel Disease]; NCT03772743)., Competing Interests: Funding Support and Author Disclosures Sahajanand Medical Technologies Ltd (SMT), Medis Medical Imaging Systems, Eukon S.r.l., Siemens Healthineers, General Electric (GE) Healthcare, and Insight Lifetech provided unrestricted funding to the study sponsor for the conduction of the trial. These companies had no involvement in the trial design, data collection, analysis, interpretation, or writing of the manuscript. Dr Campo has received research grants and personal fees from Abbott Vascular, GADA, Menarini, Amgen, Daichi-Sankyo, and Sanofi, outside the submitted work. Dr Moreno has received speaker/consulting fees from Abbott Vascular, AMGEN, AstraZeneca, Biosensors, Biotronik, Boston Scientific, Daiichi-Sankyo, Edwards, Medtronic, and Philips, outside the submitted work. Dr Biscaglia has received funding from the Italian Health Minister (Ricerca Finalizzata 2021, GR-2021-12372516) for the conduction of the Functional Coronary Angiography Guided Revascularization in STEMI trial; and has received personal fees from Abbott Vascular and Siemens Healthcare, outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

38. New risk classification adapting SCAI shock stages to patients with pulmonary embolism (RISA-PE).

Author: Párraga R, Real C, Jiménez-Mazuecos J, Vázquez-Álvarez ME, Valero E, Velázquez M, Tébar D, Salvatella N, Rumiz E, Ruiz Quevedo V, Sabatel-Pérez F, Amat-Santos I, Lozano I, Elizondo I, Andrés-Morist A, Núñez-Gil I, Portero JJ, Gonzalo N, Juárez Fernández M, Viana-Tejedor A, Ferrera C, and Salinas P
Abstract: Background: Pulmonary embolism (PE) treatment is based on risk stratification according to European Society of Cardiology (ESC) guidelines. However, emerging therapies in acute PE may require a more granular risk classification. Therefore, the objective of the present study was to propose a new RIsk claSsification Adapting the SCAI shock stages to right ventricular failure due to acute PE (RISA-PE)., Methods: This registry included consecutive intermediate-high risk (IHR) or high-risk (HR)-PE patients selected for catheter-directed interventions (CDI) from 2018 to 2023 in 15 Spanish centers (NCT06348459). Patients were grouped according to RISA-PE classification as A (right ventricular dysfunction and troponin elevation); B (A + serum lactate >2 mmol/L OR shock index ≥1); C (persistent hypotension); D (obstructive shock); and E (cardiac arrest). In-hospital adverse events were assessed to evaluate RISA-PE performance., Results: A total of 334 patients were included (age 62.1±15.2 years, 55.7% males). The incidence of in-hospital all-cause death was progressively higher with increasing RISA-PE stage (1.2%, 6.4%, 19.0%, 25.6%, and 57.7% for stages A, B, C, D, and E, respectively, P value for linear trend<0.001). However, using the ESC classification, there was an abrupt difference between IHR- and HR-PE patients regarding mortality (4.3% vs. 29.3%, P<0.001). The incidence of in-hospital major bleeding and acute kidney injury followed a similar pattern., Conclusions: The user-friendly RISA-PE classification may improve the granularity in stratifying PE patients' risk and warrants evaluation in larger studies with different therapeutic approaches in order to detect its utility as a decision-making scale.
Published: 2024
Full Text: View/download PDF

39. Thrombocytopenia after transcatheter aortic valve implantation.

Author: Tirado-Conte G, Panagides V, Vergara-Uzcategui CE, Veiga Fernández G, Vílchez JP, Cepas-Guillén P, Oteo JF, Barrero A, Marroquín L, Farjat-Pasos JI, Arslani K, Jiménez-Quevedo P, Núñez-Gil I, Mejía-Rentería H, de la Torre Hernández JM, Díez Gil JL, Regueiro A, Amat-Santos I, Fernández-Ortiz A, Eid-Lidt G, de Backer O, Rodés-Cabau J, and Nombela-Franco L
Abstract: Introduction and Objectives: Thrombocytopenia frequently occurs after transcatheter aortic valve implantation (TAVI) but its impact is poorly understood. We aimed to analyze the incidence, clinical impact, and predictors of acquired thrombocytopenia after TAVI., Methods: This retrospective multicenter registry included 3913 patients undergoing TAVI with a baseline platelet count of ≥ 100 *10 9 /L. Acquired thrombocytopenia was defined as a decrease in baseline platelet count of ≥ 50% (early nadir ≤ 3 days and late nadir ≥ 4 days) post-TAVI. The primary endpoint was 30-day all-cause mortality and secondary endpoints were procedural safety and 2-year all-cause mortality., Results: The incidence of acquired thrombocytopenia was 14.8% (early nadir: 61.5%, late nadir: 38.5%). Thirty-day mortality occurred in 112 (3.0%) patients and was significantly higher in those with thrombocytopenia (8.5% vs 2.0%, adjusted OR, 2.3; 95%CI, 1.3-4.2). Procedural safety was lower and 2-year mortality was higher in patients with thrombocytopenia vs those without (52.1 vs 77.0%; P <.001, and 30.2% vs 16.8%; HR, 2.2, 95%IC, 1.3-2.7) and especially in those with late nadir thrombocytopenia (45.8% vs 54.5%; P=.056, and 38.6% vs 23.8%, HR, 2.1; 95%CI, 1.5-2.9). Independent predictors of thrombocytopenia comprised baseline and procedural factors such as body surface area, absence of diabetes, poorer renal function, peripheral vascular disease, nontransfemoral access, vascular complications, type of transcatheter heart valve, and earlier TAVI procedures., Conclusions: Acquired thrombocytopenia was common (15%) after TAVI and was associated with increased short- and mid-term mortality and decreased procedural safety. Moreover, late thrombocytopenia compared with early thrombocytopenia was associated with significantly worse clinical outcomes. Further investigations are needed to elucidate the etiologic mechanisms behind these findings., (Copyright © 2024 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
Published: 2024
Full Text: View/download PDF

40. Balloon-Expandable vs Self-Expanding Valves for Transcatheter Treatment of Sievers Type 1 Bicuspid Aortic Stenosis.

Author: Buono A, Zito A, Kim WK, Fabris T, De Biase C, Bellamoli M, Montarello N, Costa G, Alfadhel M, Koren O, Fezzi S, Bellini B, Massussi M, Scotti A, Bai L, Costa G, Mazzapicchi A, Giacomin E, Gorla R, Hug K, Briguori C, Bettari L, Messina A, Boiago M, Villa E, Renker M, Garcia Gomez M, Fraccaro C, De Rosa ML, Patel V, Trani C, De Carlo M, Laterra G, Latini A, Pellegrini D, Ielasi A, Orbach A, Landes U, Rheude T, Testa L, Amat Santos I, Mangieri A, Saia F, Favero L, Chen M, Adamo M, Latib A, Sonia Petronio A, Montorfano M, Makkar RR, Mylotte D, Blackman DJ, Burzotta F, Barbanti M, De Backer O, Tchètchè D, Maffeo D, and Tarantini G
Abstract: Background: Balloon-expandable valves (BEVs) and self-expanding valves (SEVs) have different features that may impact the outcomes of patients with Sievers type 1 bicuspid aortic valve (BAV) stenosis undergoing transcatheter aortic valve replacement., Objectives: This study sought to compare procedural and clinical outcomes of BEVs and SEVs in Sievers type 1 BAV stenosis., Methods: AD-HOC (Characteristics, Sizing, and Outcomes of Stenotic Raphe-Type Bicuspid Aortic Valves Treated With Transcatheter Device Implantation) is an observational registry enrolling patients with Sievers type 1 BAV stenosis undergoing transcatheter aortic valve replacement with current-generation BEVs and SEVs at 24 international centers. A 1:1 propensity score matching analysis was performed to adjust for baseline imbalances. The primary endpoint was midterm major adverse events, defined as a composite of all-cause death, neurologic events, or hospitalization for heart failure., Results: Among 955 eligible patients, propensity score matching resulted in 301 pairs. At a median follow-up of 1.3 years, BEVs and SEVs had a similar risk of major adverse events (BEV vs SEV: HR: 0.75; 95% CI: 0.49-1.16; P = 0.200). Technical success was similar (OR: 1.38; 95% CI: 0.63-3.04; P = 0.421). At 30 days, BEVs were associated with a lower risk of new permanent pacemaker implantation (OR: 0.42; 95% CI: 0.24-0.72; P = 0.002) and moderate or greater paravalvular regurgitation (OR: 0.16; 95% CI: 0.05-0.48; P = 0.001) but a higher risk of severe patient-prosthesis mismatch (OR: 3.03; 95% CI 1.02-8.95; P = 0.045)., Conclusions: Current-generation BEVs and SEVs proved similar technical success and midterm clinical efficacy in Sievers type 1 BAV stenosis. Compared to SEVs, BEVs were associated with less permanent pacemaker implantation and moderate or greater paravalvular regurgitation but with more severe patient-prosthesis mismatch., Competing Interests: Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

41. Impact of gender on in-hospital and long-term outcomes after transcatheter aortic valve implantation: an analysis of the Spanish TAVI registry.

Author: Gabani R, Brugaletta S, Bujak K, Pèrez-Vizcayno MJ, Jiménez-Quevedo P, Arévalos V, Muñoz-García E, Trillo-Nouche R, Del Valle R, de la Torre Hernández JM, Salido L, Gutiérrez E, Pan M, Sánchez-Gila J, García Del Blanco B, Moreno R, Blanco Mata R, Oteo JF, Amat-Santos I, Regueiro A, Ten F, Nogales JM, Fernández-Nofrerías E, Andraka L, Ferrer MC, Pinar E, Romaguera R, Cuellas Ramón C, Alfonso F, García-Blas S, Piñero A, Ignasi J, Díaz Mèndez R, Bordes P, Meseguer J, Nombela-Franco L, and Sabaté M
Abstract: Introduction and Objectives: Impact of gender on long-term outcomes after transcatheter aortic valve implantation (TAVI) remains uncertain. We aimed to investigate gender-specific differences in TAVI and its impact on outcomes., Methods: This analysis used data from the prospective Spanish TAVI registry, which included consecutive TAVI patients treated in 46 Spanish centers from 2009 to 2021. The primary endpoint was all-cause mortality at 12 months. Secondary endpoints included in-hospital and 30-day mortality and TAVI-related complications. Adjusted logistic and Cox regression analyses were performed., Results: The study included 12 253 consecutive TAVI patients with a mean age of 81.2±6.4 years. Women (53.9%) were older, and had a higher STS-PROM score (7.0±7.0 vs 6.2±6.7; P < .001) than men. Overall, the TAVI-related complication rate was similar between women and men, with specific gender-related complications. While women more frequently developed in-hospital vascular complications (13.6% vs 9.8%; P <.001) and cardiac tamponade (1.5% vs 0.6%; P=.009), men showed a higher incidence of permanent pacemaker implantation (14.5% vs 17.4%; P=.009). There was no difference in all-cause mortality either in hospital (3.6% vs 3.6%, adjusted OR, 1.01; 95%CI, 0.83-1.23; P=.902), at 30 days (4.2% vs 4.2%, adjusted OR, 0.90; 95%CI, 0.65-1.25; P=.564) or at 1 year (11% vs 13%, adjusted HR, 0.94; 95%CI, 0.80-1.11; P=.60)., Conclusions: Women treated with TAVI are older and have more comorbidities than men, leading to distinct complications between genders. Nevertheless, all-cause mortality in the short-term and at 1-year was similar between men and women., (Copyright © 2024 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
Published: 2024
Full Text: View/download PDF

42. Performance of balloon-expandable transcatheter bioprostheses in inoperable patients with pure aortic regurgitation of a native valve: The BE-PANTHEON international project.

Author: Poletti E, Amat-Santos I, Criscione E, Popolo Rubbio A, García-Gómez M, Orzalkiewicz M, Pan M, Sisinni A, Squillace M, Del Blanco BG, Bruno F, Panoulas V, Pracon R, De Backer O, Taramasso M, Costa G, Barbanti M, Van Mieghem NM, Regazzoli D, Mangieri A, Scotti A, Latib A, Saia F, Bedogni F, and Testa L
Abstract: Background: The off-label utilization of transcatheter heart valve (THV) devices for the treatment of inoperable or high-surgical risk patients with pure native aortic valve regurgitation (NAVR) has demonstrated suboptimal outcomes, both with self- and balloon-expandable (BE) devices. The aim of this study is to compare the use of different BE scaffolds in treating pure NAVR., Methods: Consecutive patients with pure severe NAVR who were deemed to be at high-risk and were treated with last-generation BE-THVs among seventeen Centers in Europe and US. Technical and device success rates were the primary objectives., Results: Between February 2018 and July 2023, among 144 patients, 41 (28 %) received a MyVal device and 103 (72 %) were treated with a Sapien THV. Patients treated with a MyVal THV had an extra-large annulus more frequently compared to the Sapien group (49%vs.20 %, p < 0.001). Technical and device success rates were 90 % and 81 %, respectively, p > 0.1. The rate of THV migration/embolization (MyVal 4.9%vs. Sapien 11 %, p = 0.4) and second valve needed (4.9%vs.7.8 %, p = 0.7) were numerically lower in the MyVal group, whereas the rate of at least moderate paravalvular leak (15%vs.7.8 %, p = 0.2) and permanent pacemaker implantation (25%vs.18 %, p = 0.16) were numerically higher in the Myval group., Conclusions: Off-label use of BE devices for pure NAVR represents a potential alternative in high-risk patients in the absence of dedicated devices. However, BE in NAVR is associated with suboptimal outcomes. The availability of larger THV sizes may introduce transcatheter aortic valve replacement as an effective treatment for patients traditionally deemed unsuitable., Non-Standard Abbreviations and Acronyms: AR = aortic regurgitation, BE = balloon-expandable, NAVR = native aortic valve regurgitation, PM = pacemaker, TAVR = transcatheter aortic valve replacement, THV = transcatheter heart valve, TVEM = transcatheter valve embolization and migration, VARC-3 = Valve Academic Research Consortium 3., Competing Interests: Declaration of competing interest AS has served as a consultant for Edwards Lifesciences and NeoChord Inc. AL has served on the advisory board for Medtronic, Abbott Vascular, Boston Scientific, Edwards Lifesciences, Shifamed, NeoChord Inc., V-dyne, and Philips. LT is proctor/consultant for Abbot, BSCI, Medtronic, Meril. The other authors did not report any conflict of interest., (Copyright © 2024. Published by Elsevier Inc.)
Published: 2024
Full Text: View/download PDF

43. A reduced order model formulation for left atrium flow: an atrial fibrillation case.

Author: Balzotti C, Siena P, Girfoglio M, Stabile G, Dueñas-Pamplona J, Sierra-Pallares J, Amat-Santos I, and Rozza G
Subjects: Humans, Hemodynamics, Computer Simulation, Blood Flow Velocity, Atrial Fibrillation physiopathology, Models, Cardiovascular, Heart Atria physiopathology
Abstract: A data-driven reduced order model (ROM) based on a proper orthogonal decomposition-radial basis function (POD-RBF) approach is adopted in this paper for the analysis of blood flow dynamics in a patient-specific case of atrial fibrillation (AF). The full order model (FOM) is represented by incompressible Navier-Stokes equations, discretized with a finite volume (FV) approach. Both the Newtonian and the Casson's constitutive laws are employed. The aim is to build a computational tool able to efficiently and accurately reconstruct the patterns of relevant hemodynamics indices related to the stasis of the blood in a physical parametrization framework including the cardiac output in the Newtonian case and also the plasma viscosity and the hematocrit in the non-Newtonian one. Many FOM-ROM comparisons are shown to analyze the performance of our approach as regards errors and computational speed-up., (© 2024. The Author(s).)
Published: 2024
Full Text: View/download PDF

44. Combined Use of MITRACLIP and Ventricular ASSIST Devices in Cardiogenic Shock: MITRA-ASSIST Registry.

Author: Rivero-Santana B, Jurado-Roman A, Pascual I, Li CH, Jimenez P, Estevez-Loureiro R, Cepas-Guillén P, Benito-González T, Serrador A, De La Torre-Hernandez JM, Avanzas P, Fernandez-Peregrina E, Nombela L, Caneiro-Queija B, Freixas X, Fernandez-Vazquez F, Amat-Santos I, Lee DH, Leon V, Arzamendi D, Moreno R, and Galeote G
Abstract: Background: Patients with cardiogenic shock (CS) and mitral regurgitation (MI) have a prohibitive risk that contraindicates surgical treatment. Although the feasibility of transcatheter edge-to-edge therapy (TEER) has been demonstrated in this setting, the benefit of the combined use of TEER with mechanical circulatory support devices (MCS) has not been studied. The aim of this study was to evaluate the clinical outcomes of TEER in patients with MCS. Methods: The MITRA-ASSIST study is a retrospective multicentre Spanish registry that included patients with MR and CS who underwent TEER in combination with MCS. The primary endpoint was death from any cause at 12 months. The secondary endpoint was a composite of death from any cause or hospitalisation for heart failure at 12 months. Results: A total of twenty-four patients in nine high-volume Spanish centres (66.2 (51-82) years, 70.8% female, EuroSCORE II 20.4 ± 17.8) were included. Acute ST-elevation myocardial infarction was the main CS aetiology (56%), and the most implanted MCS was the intra-aortic balloon pump (82.6%), followed by ECMO (8.7%), IMPELLACP ® (4.3%), or a combination of both (4.3%). Procedural success was 95.8%, with 87.5% in-hospital survival. At 12-month follow-up, 25.0% of patients died, and 33.3% had a composite event of death from any cause or hospitalisation for heart failure. Conclusions: TEER in patients with concomitant CS and MR who require MCS appears to be a promising therapeutic alternative with a high device procedural success rate and acceptable mortality and heart failure readmission rates at follow-up.
Published: 2024
Full Text: View/download PDF

45. Incidence, Predictors, and Outcomes of Paravalvular Regurgitation After TAVR in Sievers Type 1 Bicuspid Aortic Valves.

Author: Zito A, Buono A, Scotti A, Kim WK, Fabris T, de Biase C, Bellamoli M, Montarello N, Costa G, Alfadhel M, Koren O, Fezzi S, Bellini B, Massussi M, Bai L, Costa G, Mazzapicchi A, Giacomin E, Gorla R, Hug K, Briguori C, Bettari L, Messina A, Villa E, Boiago M, Romagnoli E, Orbach A, Laterra G, Aurigemma C, De Carlo M, Renker M, Garcia Gomez M, Trani C, Ielasi A, Landes U, Rheude T, Testa L, Amat Santos I, Mangieri A, Saia F, Favero L, Chen M, Adamo M, Sonia Petronio A, Montorfano M, Makkar RR, Mylotte D, Blackman DJ, Barbanti M, De Backer O, Tchètchè D, Tarantini G, Latib A, Maffeo D, and Burzotta F
Subjects: Humans, Male, Female, Risk Factors, Aged, Treatment Outcome, Aged, 80 and over, Incidence, Time Factors, Heart Valve Diseases diagnostic imaging, Heart Valve Diseases surgery, Heart Valve Diseases physiopathology, Europe, Risk Assessment, Prosthesis Design, Odds Ratio, Stroke etiology, Stroke diagnosis, Heart Failure physiopathology, Heart Failure etiology, Heart Failure diagnosis, Retrospective Studies, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement instrumentation, Transcatheter Aortic Valve Replacement mortality, Aortic Valve Insufficiency physiopathology, Aortic Valve Insufficiency diagnostic imaging, Aortic Valve Insufficiency etiology, Aortic Valve Insufficiency surgery, Aortic Valve Stenosis surgery, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis physiopathology, Aortic Valve Stenosis mortality, Aortic Valve surgery, Aortic Valve diagnostic imaging, Aortic Valve physiopathology, Aortic Valve abnormalities, Bicuspid Aortic Valve Disease surgery, Bicuspid Aortic Valve Disease diagnostic imaging, Heart Valve Prosthesis, Severity of Illness Index
Abstract: Background: Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve (BAV) stenosis is technically challenging and is burdened by an increased risk of paravalvular regurgitation (PVR)., Objectives: The aim of this study was to identify the incidence, predictors, and clinical outcomes of PVR after TAVR in Sievers type 1 BAV stenosis., Methods: Consecutive patients with Sievers type 1 BAV stenosis undergoing TAVR with current-generation transcatheter heart valves (THVs) in 24 international centers were enrolled. PVR was graded as none/trace, mild, moderate, and severe according to echocardiographic criteria. The endpoint of major adverse events (MAEs), defined as a composite of all-cause death, stroke, or hospitalization for heart failure, was assessed at the last available follow-up., Results: A total of 946 patients were enrolled. PVR occurred in 423 patients (44.7%)-mild, moderate, and severe in 387 (40.9%), 32 (3.4%), and 4 (0.4%) patients, respectively. Independent predictors of moderate or severe PVR were a larger virtual raphe ring perimeter (adjusted OR: 1.07; 95% CI: 1.02-1.13), severe annular or left ventricular outflow tract calcification (adjusted OR: 5.21; 95% CI: 1.45-18.77), a self-expanding valve (adjusted OR: 9.01; 95% CI: 2.09-38.86), and intentional supra-annular THV positioning (adjusted OR: 3.31; 95% CI: 1.04-10.54). At a median follow-up of 1.3 years (Q1-Q3: 0.5-2.4 years), moderate or severe PVR was associated with an increased risk of MAEs (adjusted HR: 2.52; 95% CI: 1.24-5.09)., Conclusions: After TAVR with current-generation THVs in Sievers type 1 BAV stenosis, moderate or severe PVR occurred in about 4% of cases and was associated with an increased risk of MAEs during follow-up., Competing Interests: Funding Support and Author Disclosures Dr Aurigemma has reported speaker fees from Abbott, Medtronic, Abiomed, and Terumo. Dr Trani has been involved in advisory board meetings or received speaker fees from Medtronic, Abbott, Terumo, Daiichi-Sankyo, and Abiomed. Dr Adamo has reported speaker honoraria from Abbott Vascular and Edwards Lifesciences. Dr Burzotta has been involved in advisory board meetings or has received speaker fees from Medtronic, Abbott, Terumo, Daiichi-Sankyo, and Abiomed. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

46. QFR for the Revascularization of Nonculprit Vessels in MI Patients: Insights From the FIRE Trial.

Author: Erriquez A, Campo G, Guiducci V, Casella G, Menozzi M, Cerrato E, Sacchetta G, Moreno R, Arena M, Amat Santos I, Diez Gil JL, Scarsini R, Ruozzi M, Arioti M, Picchi A, Barbierato M, Moscarella E, Musto D'Amore S, Lanzilotti V, Cavazza C, Rezzaghi M, Cocco M, Marrone A, Verardi FM, Escaned J, Barbato E, Colaiori I, Pesenti N, Carrara G, and Biscaglia S
Subjects: Aged, Aged, 80 and over, Female, Humans, Male, Cardiac Catheterization adverse effects, Cardiac Catheterization instrumentation, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Artery Disease physiopathology, Coronary Vessels diagnostic imaging, Coronary Vessels physiopathology, Fractional Flow Reserve, Myocardial, Myocardial Infarction physiopathology, Myocardial Infarction diagnostic imaging, Prospective Studies, Risk Factors, Time Factors, Treatment Outcome, Coronary Angiography, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention instrumentation, Predictive Value of Tests
Abstract: Background: The role of quantitative flow ratio (QFR) in the treatment of nonculprit vessels of patients with myocardial infarction (MI) is a topic of ongoing discussion., Objectives: This study aimed to investigate the predictive capability of QFR for adverse events and its noninferiority compared to wire-based functional assessment in nonculprit vessels of MI patients., Methods: The FIRE (Functional Assessment in Elderly MI Patients With Multivessel Disease) trial randomized 1,445 older MI patients to culprit-only (n = 725) or physiology-guided complete revascularization (n = 720). In the culprit-only arm, angiographic projections of nonculprit vessels were prospectively collected, centrally reviewed for QFR computation, and associated with endpoints. In the complete revascularization arm, endpoints were compared between nonculprit vessels investigated with QFR or wire-based functional assessment. The primary endpoint was the vessel-oriented composite endpoint (VOCE) at 1 year., Results: QFR was measured on 903 nonculprit vessels from 685 patients in the culprit-only arm. Overall, 366 (40.5%) nonculprit vessels showed a QFR value ≤0.80, with a significantly higher incidence of VOCEs (22.1% vs 7.1%; P < 0.001). QFR ≤0.80 emerged as an independent predictor of VOCEs (HR: 2.79; 95% CI: 1.64-4.75). In the complete arm, QFR was used in 320 (35.2%) nonculprit vessels to guide revascularization. When compared with propensity-matched nonculprit vessels in which treatment was guided by wire-based functional assessment, no significant difference was observed (HR: 0.57; 95% CI: 0.28-1.15) in VOCEs., Conclusions: This prespecified subanalysis of the FIRE trial provides evidence supporting the safety and efficacy of QFR-guided interventions for the treatment of nonculprit vessels in MI patients. (Functional Assessment in Elderly MI Patients With Multivessel Disease [FIRE]; NCT03772743)., Competing Interests: Funding Support and Author Disclosures The data supporting this paper are accessible upon reasonable request to the FIRE Study Executive Committee. Sahajanand Medical Technologies Ltd, Medis Medical Imaging Systems, Eukon S.r.l., Siemens Healthineers, General Electric Healthcare, and Insight Lifetech provided unrestricted funding to the study sponsor for the conduction of the trial. These companies had no involvement in the trial design, data collection, analysis, interpretation, or writing of the manuscript. Dr Campo has received research grants and personal fees from Abbott Vascular, GADA, Menarini, Amgen, Daichii-Sankyo, and Sanofi outside of the submitted work. Dr Moreno has received speaker/consulting fees from Abbott Vascular, AMGEN, AstraZeneca, Biosensors, Biotronik, Boston Scientific, Daiichi-Sankyo, Edwards Lifesciences, Medtronic, and Philips outside of the submitted work. Dr Barbato declares speaker fees from Abbott Vascular, Boston Scientific, Insight Lifetech, outside of the submitted work. Dr Biscaglia has received funding from the Italian Health Minister (Ricerca Finalizzata 2021, GR-2021-12372516) for the conduction of the Functional Coronary Angiography Guided Revascularization in STEMI trial; and has received personal fees from Abbott Vascular outside of the submitted work., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

47. Impact of coronary calcium morphology on intravascular lithotripsy.

Author: McInerney A, Travieso A, Jerónimo Baza A, Alfonso F, Del Val D, Cerrato E, Garcia de Lara J, Pinar E, Perez de Prado A, Jimenez Quevedo P, Tirado-Conte G, Nombela-Franco L, Brugaletta S, Cepas-Guillén P, Sabaté M, Cubero Gallego H, Vaquerizo B, Jurado A, Varbella F, Jimenez M, Garcia Escobar A, de la Torre JM, Amat Santos I, Jimenez Diaz VA, Escaned J, and Gonzalo N
Subjects: Humans, Male, Female, Middle Aged, Aged, Prospective Studies, Treatment Outcome, Stents, Percutaneous Coronary Intervention methods, Coronary Vessels diagnostic imaging, Coronary Vessels pathology, Calcium, Lithotripsy methods, Tomography, Optical Coherence, Vascular Calcification diagnostic imaging, Vascular Calcification therapy, Coronary Artery Disease therapy, Coronary Artery Disease diagnostic imaging, Coronary Angiography
Abstract: Background: Coronary calcification negatively impacts optimal stenting. Intravascular lithotripsy (IVL) is a new calcium modification technique., Aims: We aimed to assess the impact of different calcium morphologies on IVL efficacy., Methods: This was a prospective, multicentre study (13 tertiary referral centres). Optical coherence tomography (OCT) was performed before and after IVL, and after stenting. OCT-defined calcium morphologies were concentric (mean calcium arc >180°) and eccentric (mean calcium arc ≤180°). The primary outcomes were angiographic success (residual stenosis <20%) and the presence of fracture by OCT in concentric versus eccentric lesions., Results: Ninety patients were included with a total of 95 lesions: 47 concentric and 48 eccentric. The median number of pulses was 60 (p=1.00). Following IVL, the presence of fracture was not statistically different between groups (79.0% vs 66.0% for concentric vs eccentric; p=0.165). The number of fractures/lesion (4.2±4.4 vs 2.3±2.8; p=0.018) and ≥3 fractures/lesion (57.1% vs 34.0%; p=0.029) were more common in concentric lesions. Angiographic success was numerically but not statistically higher in the concentric group (87.0% vs 76.6%; p=0.196). By OCT, no differences were noted in final minimum lumen area (5.9±2.2 mm 2 vs 6.2±2.1 mm 2 ; p=0.570), minimum stent area (5.9±2.2 mm² vs 6.25±2.4 mm 2 ; p=0.483), minimum stent expansion (80.9±16.7% vs 78.2±19.8%), or stent expansion at the maximum calcium site (100.6±24.2% vs 95.8±27.3%) (p>0.05 for all comparisons of concentric vs eccentric, respectively). Calcified nodules were found in 29.5% of lesions; these were predominantly non-eruptive (57%). At the nodule site, dissection was more common than fracture with stent expansion of 103.6±27.2%., Conclusions: In this prospective, multicentre study, the effectiveness of IVL followed by stenting was not significantly affected by coronary calcium morphology.
Published: 2024
Full Text: View/download PDF

48. Immediate or staged complete revascularisation in patients presenting with acute coronary syndrome by number of diseased vessels: a substudy of the BIOVASC randomised trial.

Author: Kakar H, Elscot JJ, Scarparo P, Den Dekker WK, Bennett J, Sabaté M, Esposito G, Amat-Santos I, Boersma E, Van Mieghem NM, and Diletti R
Subjects: Humans, Treatment Outcome, Coronary Artery Bypass methods, Vascular Surgical Procedures, Acute Coronary Syndrome surgery, Myocardial Infarction, Percutaneous Coronary Intervention methods, Coronary Artery Disease surgery
Abstract: Background: In patients presenting with acute coronary syndrome (ACS), the number of diseased vessels may affect the efficacy of a complete revascularisation strategy., Aims: The authors sought to evaluate the safety and efficacy of immediate complete revascularisation (ICR) and staged complete revascularisation (SCR) in patients presenting with ACS stratified by the number of diseased vessels., Methods: In this prespecified analysis of the BIOVASC trial, ICR was compared with SCR in patients with two-vessel disease (2VD) or three-vessel disease (3VD). The primary endpoint was a composite of all-cause mortality, myocardial infarction (MI), any unplanned ischaemia-driven revascularisation or cerebrovascular events at 1 year after the index procedure. Comparisons were performed using Cox regression., Results: A total of 1,525 patients were enrolled in the BIOVASC trial, of whom 1,177 presented with 2VD and 265 with 3VD. In the 2VD group, 613 patients were assigned to ICR and 564 to SCR. In the 3VD group, 117 patients were assigned to ICR and 148 to SCR. ICR and SCR led to similar results in both the 2VD (hazard ratio [HR] 0.76, 95% confidence interval [CI]: 0.50-1.13; p=0.18) and 3VD groups (HR 0.79, 95% CI: 0.39-1.59; p=0.51) (p interaction =0.91) in terms of the primary endpoint. ICR was associated with a lower rate of MI in patients with 3VD (HR 0.21, 95% CI: 0.046-0.93; p=0.04) (p interaction =0.30)., Conclusions: ICR might be an option in patients presenting with extensive 3VD and might be associated with a lower rate of myocardial infarction compared with SCR.
Published: 2024
Full Text: View/download PDF

49. OPTImized coronary interventions eXplaIn the bEst cliNical outcomEs (OPTI-XIENCE) study. Rationale and study design.

Author: Moreno R, Baptista SB, Valencia J, Gomez-Menchero A, Bouisset F, Ruiz-Arroyo JR, Bento A, Besutti M, Jimenez-Valero S, Rivero-Santana B, Olhmann P, Santos M, Vaquerizo B, Cuissetm T, Lemoine J, Pinar E, Fiarresga A, Urbano C, Marliere S, Braga C, Amat-Santos I, Morgado G, Sarnago F, Telleria M, Van Belle E, Díaz-Fernandez J, Borrego JC, Amabile N, and Meneveau N
Subjects: Humans, Prospective Studies, Prosthesis Design, Sirolimus, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Coronary Artery Disease etiology, Drug-Eluting Stents, Myocardial Infarction etiology, Percutaneous Coronary Intervention adverse effects
Abstract: Introduction: Clinical events may occur after percutaneous coronary intervention (PCI), particularly in complex lesions and complex patients. The optimization of PCI result, using pressure guidewire and intracoronary imaging techniques, may reduce the risk of these events. The hypothesis of the present study is that the clinical outcome of patients with indication of PCI and coronary stent implantation that are at high risk of events can be improved with an unrestricted use of intracoronary tools that allow PCI optimization., Methods and Analysis: Observational prospective multicenter international study, with a follow-up of 12 months, including 1064 patients treated with a cobalt‑chromium everolimus-eluting stent. Inclusion criteria include any of the following: Lesion length > 28 mm; Reference vessel diameter < 2.5 mm or > 4.25 mm; Chronic total occlusion; Bifurcation with side branch ≥2.0 mm;Ostial lesion; Left main lesion; In-stent restenosis; >2 lesions stented in the same vessel; Treatment of >2 vessels; Acute myocardial infarction; Renal insufficiency; Left ventricular ejection fraction <30 %; Staged procedure. The control group will be comprised by a similar number of matched patients included in the "extended risk" cohort of the XIENCE V USA study. The primary endpoint will be the 1-year rate of target lesion failure (TLF) (composite of ischemia-driven TLR, myocardial infarction (MI) related to the target vessel, or cardiac death related to the target vessel). Secondary endpoints will include overall mortality, cardiovascular mortality, acute myocardial infarction, TVR, TLR, target vessel failure, and definitive or probable stent thrombosis at 1 year., Implications: The ongoing OPTI-XIENCE study will contribute to the growing evidence supporting the use of intra-coronary imaging techniques for stent optimization in patients with complex coronary lesions., Competing Interests: Declaration of competing interest The following authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The rest of the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

50. Outcomes and performance of the ACURATE neo2 transcatheter heart valve in clinical practice: one-yearresults of the ACURATE neo2 PMCF Study.

Author: Kim WK, Möllmann H, Montorfano M, Ellert-Gregersen J, Rudolph TK, Van Mieghem NM, Hilker M, Amat-Santos I, Terkelsen CJ, Petronio AS, Stella P, Götberg M, Rück A, Kasel AM, Trillo R, Appleby C, Barbanti M, Blanke P, Asch FM, Modolo R, Allocco DJ, and Tamburino C
Subjects: Aged, 80 and over, Female, Humans, Male, Aortic Valve diagnostic imaging, Aortic Valve surgery, Prosthesis Design, Treatment Outcome, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Stroke etiology, Transcatheter Aortic Valve Replacement methods
Abstract: Background: Transcatheter aortic valve implantation is an effective treatment for patients with aortic stenosis; however, complications related to paravalvular leakage (PVL) persist, including increased risk of mortality, cardiovascular mortality, and rehospitalisation., Aims: We sought to evaluate the clinical outcomes and valve performance at 1 year in patients with severe aortic stenosis treated with the ACURATE neo2 valve in a post-market clinical setting., Methods: Valve Academic Research Consortium-2 safety events were assessed up to 1 year. Independent core laboratories evaluated echocardiographic measures of valve performance and hypoattenuated leaflet thickening (HALT; as measured by four-dimensional computed tomography)., Results: The study enrolled 250 patients (64% female; mean age: 81 years; baseline Society of Thoracic Surgeons risk score: 2.9±2.0%); 246 patients were implanted with ACURATE neo2. All-cause mortality was 0.8% at 30 days and 5.1% at 1 year. The 1-year rates for stroke and disabling stroke were 3.0% and 1.3%, respectively. Overall, HALT of >50% leaflet involvement of at least one leaflet was present in 9% of patients at 30 days and in 12% of patients at 1 year. No association was observed between the presence of HALT and 1-year clinical or haemodynamic outcomes. Early haemodynamic improvements were maintained up to 1 year (mean aortic valve gradient: 47.6±14.5 mmHg at baseline, 7.6±3.2 mmHg at 1 year; mean aortic valve area: 0.7±0.2 cm 2 at baseline, 1.7±0.4 cm 2 at 1 year). At 1 year, 99% of patients had mild or no/trace PVL (<1% had moderate PVL; no patient had severe PVL)., Conclusions: The study outcomes confirm favourable performance and safety up to 1 year in patients treated with ACURATE neo2 in routine clinical practice. (ClinicalTrials.gov: NCT04655248).
Published: 2024
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

121 results on '"Amat-Santos I"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources